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Abstract 
	
One of the major medical advances of the twentieth century is the development 
of cardiac transplantation. Cardiac transplantation is the definitive treatment for 
end-stage heart disease. Cardiac transplantation relies on organs procured 
from Brain Dead Donors (DBD). Donation after Circulatory Death (DCD) organs 
are being increasingly used for renal, liver and lung transplantation. Hearts from 
DCD donors have not been utilized as there is a fear that they will have 
sustained irreversible myocardial injury post cardiac arrest. We have a limited 
understanding of Post cardiac arrest myocardial depression due to the lack of a 
good physiological model of the disease. Objective: To develop a model of in-
vivo cardiac arrest and resuscitation in order to characterize the biology of the 
associated myocardial dysfunction and test potential therapeutic strategies. 
Methods and Results: We developed a rodent model of post arrest myocardial 
depression (DCD model) using extracorporeal membrane oxygenation for 
resuscitation, followed by invasive haemodynamic measurements. In isolated 
cardiomyocytes, we assessed mechanical load and Ca2+-induced Ca2+ 
release (CICR) simultaneously using the microcarbon fiber technique and 
observed reduced function and myofilament calcium sensitivity in the post arrest 
group. Additionally, in contrast with findings from Langendorff models of 
ischemia-reperfusion, there is a marked augmentation of CICR in isolated cells. 
This increase in calcium serves to maintain contraction in the face of 
myofilament dysfunction and, it seems to be mediated by autophosphorylation 
of calcium-calmodulin protein kinase II (CAMKII). It is further dependent on 
ryanodine receptor calcium but not PKA leading us to speculate that it is 
triggered by adrenergic activation but maintained by CAMKII. Finally, activation 
of aldehyde-dehydrogenase II by the small molecule Alda-1 dramatically 
improved whole animal and cellular contractile performance after arrest, and 
restored CICR to close to normal levels. Conclusions: Cardiac arrest and 
reperfusion lead to calcium cardiac memory, which support cardiomyocyte 
contractility in the face of post arrest myofilament calcium sensitivity. Alda-1 
mitigates these effects and improves outcome. 
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CHAPTER 1. INTRODUCTION 		
One of the major medical advances of the twentieth century is the 
development of cardiac transplantation. Since its introduction this procedure 
has improved and extended the lives of patients suffering from heart failure 
and despite advances in medical therapy cardiac transplantation still 
remains the definitive treatment for end-stage heart disease. Cardiac 
transplantation relies on donors and their families agreeing to donate their 
organs. 
 
There are three different ways for people to donate organs for 
transplantation, these are 
• Brain stem death – This is where a person no longer has activity in 
their brain stem due to a severe brain injury. They have permanently 
lost the potential for consciousness and the capacity to breathe. This 
may happen even when a ventilator is keeping the person's heart 
beating and oxygen is circulated through their blood.  This group of 
donors are called DBD (Donation after Brain Stem Death) donors 
• Circulatory death – Is the irreversible loss of function of the heart and 
lungs after a cardiac arrest from which the patient cannot or should 
not be resuscitated. It can also be the planned withdrawal of life-
sustaining treatment from a patient within the Intensive Care Unit or 
the Emergency Department. These donors are known as DCD 
(Donation after Circulatory Death) donors. 
	 2	
• Living donation - Whilst you are still alive you can choose to donate a 
kidney, a small section of your liver, discarded bone from a hip or 
knee replacement and also your amniotic membrane (placenta).  
 
The biggest hurdle to treating end-stage heart failure with transplantation is 
the shortage of suitable donor organs.1 Currently heart transplantation relies 
solely on the DBD donors as a source of organs. Over the past fifteen years 
DCD donors have been a fruitful source of organs substantially increasing 
the number of successful renal, liver and lung transplantations.2-6 DCD 
donors suffer a neurological insult, however, this falls short of fulfilling the 
criteria for brain-stem death. Due to concerns that periods of ischemia 
following circulatory arrest may result in severe myocardial injury, donation 
of hearts after circulatory death (DCD) are not used.  However, the earliest 
successful heart transplants, including the first performed in the world in 
1967, utilised organs which had been removed after cardiac arrest and 
confirmation of death of the donor.7 Boucek et al in 2008 reported a series of 
three successful paediatric heart transplantations from donors who had died 
from cardio-circulatory causes.8 In 2009, in-situ resuscitation of an adult 
human heart donated after circulatory death with subsequent weaning from 
cardio- pulmonary support was reported.9 If hearts post DCD can be 
resuscitated sufficiently this would greatly improve the number of available 
hearts for transplantation. It is estimated that the use of DCD hearts may 
increase the number of heart transplants by up to 15%.10 The focus of my 
investigation was to ascertain whether hearts sourced from a DCD donor 
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could be resuscitated and recover function in order to allow for successful 
transplantation. 
 
1.1. Organ donation 	
Solid organ transplantation was pioneered through the use of organs from 
DCD donors in the 1960’s. In 1968 the Uniform Anatomic Gift Act allowed 
adults to designate their organs for transplantation after legal declaration of 
their death.11 The Harvard Criteria for irreversible coma were developed in 
1968 and two different methods for defining death were established.12 Death 
was either defined as irreversible cessation of all brain function or the 
irreversible and simultaneous loss of circulatory and respiratory function. 
Prior to the development of brain-stem death criteria, organs were 
predominantly procured under emergent circumstances after the declaration 
of death. The acceptance of brain-stem death rapidly led to abandonment of 
organ procurement from DCD donors as organ retrieval could occur under 
more controlled circumstances in heart beating donors. It was felt that this 
practise would be associated with improved organ viability and translate into 
superior clinical outcomes. The reintroduction of organ donation from DCD 
donors was first evident in the 1980’s and was instituted in response to 
family requests for organ donation.13-15  However the realisation that the 
demand for donor organs was beginning to exceed the supply invigorated 
the development of further programs of transplantation from DCD donors 
worldwide.16,17 A decrease in the incidence of brain death began to 
compound the problems of donor organ shortage, further increasing the 
importance of alternative sources for organ donation. Improvements in 
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neuro-critical care have resulted in a group of patients with devastating 
neurological injury that do not progress towards brain death. The adoption of 
protocols for DCD donation avoids the loss of viable and potentially 
transplantable organs from this group of patients with severe neurological 
insults.18  
 
 
1.2. Cardiac transplantation – UK 
	
The UK national transplant data has shown that across all organs the total 
number of deceased donors and transplants fell in 2014/15 for the first time 
in 11 years.19 This drop may reflect an increasing number of transplants 
performed over the last 10 years. In the most recent year there have been 
fewer transplants but an increasing number of patients have been 
suspended from the transplant list. Donor and transplant numbers from April 
2005 to March 2015 and the number of patients registered on the transplant 
lists are shown in Figure 1.1. There were 169 fewer deceased donor 
transplants in 2014-2015 than in the previous year, representing a 5% 
decrease. The corresponding decrease in the number of deceased donors 
was 3%.  
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FIGURE 1-1 - NUMBER OF DECEASED DONORS AND TRANSPLANTS IN THE UK, 1 
APRIL 2005 - 31 MARCH 2015, AND PATIENTS ON THE ACTIVE TRANSPLANT LIST AT 
31 MARCH 
 
When looking across the board at the different types of donors from 2005 -
2015 it is clearly evident that there has been a substantial increase in the 
number of DCD donors compared to DBD donors.19 Figure 1.2 shows the 
number of deceased and living donors in the UK, 1April 2005 – 31 March 
2015. 
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FIGURE 1-2 - NUMBER OF DECEASED AND LIVING DONORS IN THE UK, 1 APRIL 
2005 - 31 MARCH 2015 
 
Organs for cardiac transplantation have traditionally come from DBD donors. 
Heart transplantation is threatened by a shortage of donor hearts.20 Figure 
1.3 shows the number of patients on the active transplant list as of 31st 
March each year between 2006 and 2015. The number of patient waiting for 
a heart transplant has increased substantially from 93 in 2009 to 267 in 
2015. 21 
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FIGURE	1-3 - NUMBER OF PATIENTS ON ACTIVE TRANSPLANT LIST AT 31 MARCH 
EACH YEAR, 2006 TO 2015 
 
The figure 1.4 below shows that the number of heart transplantations in the 
UK remained stable from 2005 – 2012, from 2013 there was an increase in 
number of hearts transplanted. This increase from 2013 onwards may be 
due to the implementation of the “Scout” Pilot Programme.22 Previous 
studies have demonstrated that early aggressive donor management could 
lead to increased utilisation of some donor hearts.23-25 A UK pilot programme 
was initialised in 2013 which involves sending a member of the 
cardiothoracic retrieval team, the ‘scout’, to the donor intensive care unit as 
soon as consent for organ donation is obtained. Scouts perform donor 
optimisation with the aim to 1) increase the number of donor hearts retrieved 
and transplanted and 2) improve the quality of donor hearts retrieved.  
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FIGURE	1-4	-	NUMBER	OF	ADULT	HEART	TRANSPLANTS	IN	THE	UK,	BY	FINANCIAL	YEAR,	1	APRIL	
2005	TO	31	MARCH	2015		
 
Figure 1.4 -  
Once a patient is placed on the heart transplant waiting list, a suitable donor 
heart may come along in a few days or it may take years. Unfortunately 
suitable hearts do not become available for everyone who is on the waiting 
list. About half the people accepted onto the waiting list receive a transplant 
within 3 years. 26 Some people on the transplant list who are too unwell to 
leave hospital and will have to stay in as inpatients until their transplant can 
be done go onto an “Urgent Heart Allocation” waiting list. Priority is given to 
these patients. 
 
Figure 1.5 below shows the number of adult heart transplants in the UK from 
2005 – 2015 based on the patients’ urgency status.21 It shows that the 
chance of a patient receiving a heart transplant while on the non-urgent 
waiting list is reducing year on year.  
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FIGURE	1-5	- NUMBER OF ADULT HEART TRANSPLANTS IN THE UK, BY FINANCIAL 
YEAR AND URGENCY STATUS, 1 APRIL 2005 TO 31 MARCH 2015 
 
Not all patients placed on the transplant list get transplanted. The figure 1.6 
below shows the outcomes of 88 new non-urgent heart registrations to the 
waiting list from 1 April 2011 to 31 March 2012. 21 The chart shows the 
proportion of patients transplanted or still waiting six months, one, two and 
three years after joining the list. It also shows the proportion removed from 
the transplant list (typically because they become too unwell for transplant) 
and those who died while on the transplant list. Within six months of listing, 
30% of non-urgent heart patients were transplanted while 9% died waiting. 
Three years after listing only 48% received a transplant.  
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FIGURE	1-6 - POST-REGISTRATION OUTCOME FOR 88 NEW NON-URGENT HEART ONLY 
REGISTRATIONS MADE IN THE UK, 1 APRIL 2011 TO 31 MARCH 2012 
 
1.3. Cardiac arrest: the final pathway  
	
All DCD donors will succumb to cardiac arrest prior to being declared dead. 
Therefore a good starting point to investigating these patients is to look at 
cardiac arrest in the general population. Sudden cardiac arrest is a major 
cause of death in the Western World.27 Much effort has gone into both 
aborting and resuscitating patients after cardiac arrest, but mortality after 
resuscitation remains 50% for out of hospital and 67% for in-hospital 
arrest.28,29 This excess mortality after resuscitation is reflected in the post-
cardiac arrest syndrome (PCAS),28 a condition that potentially encompasses: 
1) post-arrest central nervous system dysfunction, 2) post-arrest 
ischemia/reperfusion (I/R), 3) post-myocardial arrest dysfunction (PMAD); 
and 4) continuation of the factors precipitating sudden cardiac arrest. PMAD 
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is believed to be a form of myocardial stunning30,31 thought to result from a 
rightward shift in the myofilament calcium sensitivity curve.32 This stunning 
has been observed similarly for hypoxic arrest, but also following ventricular 
fibrillation as well.33  
 
In the heart, contraction relies on extracellular Ca entering the cytoplasm 
through voltage-gated L-type Ca channels. This Ca influx induces opening of 
ryanodine receptors (RyR), causing them to release Ca stored in the 
sarcopasmic reticulum. Figure 1.7 shows an illustration of this.34 
	
FIGURE	1-7	SCHEMATIC	OF	A	CARDIAC	MUSCEL	CELL.	FORMED	BY	L-TYPE	CA	CHANNELS	(LTCC)	 IN	
THE	 T-TUBULAR	MEMBRANE	 AND	 RYRS	 IN	 THE	 APPOSED	 JUNCTIONAL	 SR	 (JSR).	 EXTRACELLULAR	
CA	 ENTERING	 THROUGH	 LTCC	 TRIGGERS	 RYRS	 TO	 OPEN,	 RELEASEING	 SR	 CA	 INTO	 THE	 DIADIC	
SPACE	(DS)	AND	MYOPLASM	(MYO)	TO	ACTIVATE	THE	MYOFILAMENTS	(MF).	CA	IS	THEN	PUMPED	
BACK	 INTO	THE	NON-JUNCTIONAL	SR	(NSR)	BY	A	CA	PUMP	(SERCA2A)	OR	EXTRUDED	FROM	THE	
CELL	VIA	NA/CA	EXCHANGE	(NCX).		
At a cellular level, it is hypothesized that oxidative stress contributes to 
cytosolic calcium overload which leads to reversible myofilament dysfunction 
and irreversible cell death,35,36 the last mediated by mitochondrial calcium 
loading and initiation of the cell death pathway.37 Calcium overload has been 
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explained by two processes: reverse mode operation of the sodium calcium 
exchanger (NCX) related to intracellular sodium overload during ischemia 
and sarcoplasmic reticulum ATPase (SERCA) dysfunction related to ATP 
depletion.38 Importantly, however, ryanodine receptor (RyR) dependent 
calcium release has also been shown to support reversible injury,39 and at 
the same time these processes can promote irreversible injury via 
calcium/calmodulin dependent protein kinase II (CAMKII) signalling 
pathways. The relationship between NCX induced calcium overload and 
augmentation of calcium induced calcium release (CICR) is critical because 
CICR generates systolic and diastolic levels an order of magnitude higher in 
localized domains on a beat to beat basis than that which has been 
predicted to occur during the very brief (relative to the persistent PMAD 
phenotype) NCX induced cytosolic calcium overload associated with I/R. 
However, despite that biochemical pathways modulated during I/R would 
predict augmented CICR, no long lasting changes in CICR have been 
demonstrated following reperfusion40 except for one early report.38,41 One 
possible reason for this is that much work in I/R has relied on the explanted 
Langendorff preparations circulated with saline. The present experiments 
were carried out in an attempt to overcome some of these limitations. 
Specifically, because CAMKII signalling has been linked to beta-adrenergic 
signalling under pathological conditions,42 and because sudden cardiac 
arrest has been associated with dramatic elevations in catecholaminergic 
signalling,43 we felt that a model including the neurohormonal axis was 
important. In addition, to date most single cell studies have been carried out 
using unloaded cardiac mycoytes. Here, we use an in vivo model of cardiac 
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arrest with resuscitation using extracorporeal membrane oxygenation 
(ECMO) and examined both cellular force and CICR in isolated, loaded 
ventricular myocytes. 
 
1.4. In Situ Optical Mapping of Voltage and Calcium in the 
Heart  
 
As we believe that the neurohormonal axis is important we wanted to 
measure CICR and voltage in-vivo. Electrophysiological testing is a mainstay 
of clinical arrhythmia diagnosis. For simple arrhythmias, this involves a 
limited number of intracardiac electrogram measurements. But for complex 
arrhythmia, where mechanisms often are associated with underlying 
structural heart disease, spatially-resolved electroanatomic mapping (EAM) 
improves the efficacy of ablation.44  The principle behind EAM relies on 
registering electrical measurements in three-dimensional space to determine 
the tissue location underlying the arrhythmia focus. However, EAM catalogs 
the spatial context of electrical signals using an external localization system 
and triangulates position relative to a reference patch placed externally,45 
rather than by directly visualizing underlying cardiac tissue anatomy and 
physiology simultaneously.44  
 
By comparison, basic science studies of arrhythmia have tended to rely on 
the higher spatiotemporal resolution of optical mapping using fluorescent 
probes both to image anatomy directly and to measure relevant 
physiological parameters such as transmembrane voltage (Vm) and 
intracellular calcium ([Ca2+]i) dynamics.46,47  Using the isolated Langendorff-
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perfused mammalian heart, optical mapping of these two key parameters 
has played a pivotal role in arrhythmia research.48,49  Vm mapping has also 
been used to delineate normal, peri-infarct, and scarred tissue rapidly in the 
in vitro setting.50  Yet, the use of optical mapping in vivo has only been 
published once to our knowledge (in 1998).51  In our view, this is largely 
because it is experimentally challenging. However, a number of continued 
technological developments have now made the applicability of optical 
mapping to in vivo preparations more feasible, opening the door to beginning 
the process towards clinical development of an optical mapping tool 52. 
Specifically, second-generation voltage-sensitive dyes with enhanced photo-
stability and emission spectra in the near-infrared range have been 
developed, making them suitable for imaging in the presence of blood 53. In 
addition, modern camera frame-rates permit simultaneous multi-colour 
imaging using a single detector,54 in particular if combined with multi-band 
emission filters for optical mapping.55 Moreover, conventional light sources 
can be replaced now by powerful light-emitting-diodes (LEDs) which we and 
others have demonstrated to offer stable illumination that can also be 
switched on or off with nanosecond-microsecond response times, simplifying 
multi-parametric imaging.56  Based on these developments, in combination 
with a multi-band emission filter, we present a multi-parametric single-
camera multi-LED imaging system and show its suitability for in vivo cardiac 
electrophysiology data acquisition.  
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1.5. Hypothesis 
	
Our hypothesis is that the DCD heart can be resuscitated after circulatory 
arrest and recover sufficient function to allow for transplantation, increasing 
the much needed donor pool to meet current demands. As cytosolic calcium 
overload which leads to reversible myofilament dysfunction and irreversible 
cell death is central to the functioning of the organ is would seem 
appropriate to try and minimise the calcium overload and improve the 
function of the heart. To test our hypothesis we developed small animal 
model of DCD heart resuscitation. For purposes of control we utilized a small 
animal model of DBD. Following global myocardial ischemia in the DCD we 
instituted in-vivo extracorporeal membrane oxygenation (ECMO) reperfusion 
to resuscitate the heart. Load-independent contractility of DBD and DCD 
hearts was acquired using pressure-volume conductance catheters. In 
addition we examined cellular force in vitro using microcarbon fibre 
assessment simultaneously with CICR measurements  
 
The forthcoming chapters outline the methodology and the results of our 
investigation into the feasibility of resuscitating hearts from DCD donors. Our 
aim was to determine the suitability of these organs for clinical heart 
transplantation and ascertain any potential targets for therapeutic 
intervention.  
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CHAPTER 2. METHODS 
 
This Chapter contains all the methodologies used for experimental 
procedures and investigations in this thesis. 
 
2.1. RATS 
Studies and ethics were approved by the Stanford University Administrative 
Panel on Laboratory Animal Care and conform to the Guide for the Care and 
Use of Laboratory Animals published by the National Institutes of Health. 
Experimental protocols were submitted to the Administrative Panel on 
Laboratory Animal Care (APLAC) at Stanford University and subsequently 
approved prior to conducting our investigation.  
 
2.1.1. SOURCE OF ANIMALS 
Male Sprague-Dawley rats obtained from Charles River Laboratories, USA 
were utilized for my experiments.  
 
2.1.2. HOUSING 
Animals were housed at the Falk Cardiovascular Research Institute (CVI), 
Stanford University Medical Center. Temperature controlled cages (20oC to 
22oC) were used and the maximum number of animals per cage was limited 
to three. A 12-hour light - dark cycle was used and animals were given free 
access to sterile water.  
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2.1.3.  DIET 
All rats were given unlimited access to formulated chow. The composition in 
g/kg was: cereal products 769.5, Hipro soya 140, animal proteins 50, soy oil 
8 and mineral mix 32.5)  
 
2.1.4. EXPERIMENTAL SURGERY 
Operations were performed in 12-14 week old male Sprague-Dawley rats 
with an approximate weight of 250 - 300 grams. All procedures were 
undertaken only after approval of the experimental protocol by our 
institutional APLAC committee.  
 
 
2.2. RODENT MODEL OF CARDIAC RESUSCITATION AFTER 
CIRCULATORY ARREST IN THE DCD DONOR 
 
2.2.1. Ventilation and venous access 
The animal was placed in an anaesthetic chamber for induction with 
isoflurane. The isoflurane vaporizer was adjusted for insufflation of 2-3% 
isoflurane with an oxygen flow rate of 1-1.5 L/min. After adequate 
anaesthesia was achieved the animal was removed from the chamber and 
weighed. Following this the animal was transferred to the operating area and 
placed on an electric heat pad in a supine position. A nose cone was fitted 
onto the animal and maintenance of anaesthesia was achieved with 1-2% 
isoflurane. Oxygen was delivered at a flow rate of 1-2 L/minute. Adequacy of 
anaesthesia was ensured by a foot pinch manoeuvre and any reaction to 
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pain was carefully observed. The position of the animal was then secured to 
the operating area with tape. The temperature probe from the heat pad 
(ML295/R homeothermic controller and plate, ADInstruments) was inserted 
into the rectum to monitor body temperature, which was maintained between 
35.5oC and 37oC. 
 
A small skin incision was made over the right groin allowing femoral vessels 
to be identified in the inguinal region. Both femoral artery and vein were 
dissected out. The inguinal ligament was reflected superiorly to better 
visualise the vessels proximally. The distal end of the femoral vein was 
ligated with a 5.0 silk and a small vascular clamp was placed proximally. 
Following a small venotomy the vessel was cannulated with polyethylene 
tubing (PE 20). The proximal clamp was released and the tubing advanced 
further in, this venous access line was secured in place using 5.0 silk ties. 
The distal end of the tubing was connected to a 28 gauge needle and a 1cc 
syringe. Adequacy of venous access was assessed by aspirating venous 
blood and injecting 0.5ml of 0.9% normal saline. This establishes venous 
access for administration of fluids and medication.  
 
2.2.2. Tracheostomy and mechanical ventilation 
A cervical incision was made using dissecting scissors. Blunt dissection was 
used to expose the trachea. Microsurgical scissors were used to make a 
small transverse tracheotomy. A 16 gauge intravenous catheter was inserted 
into the trachea and connected to previously assembled ventilator tubing 
(Figure 2.1). Mechanical ventilation was commenced using a Harvard 
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Apparatus 683 small animal ventilator. The ventilation rate was set at 60 
strokes per minute with a tidal volume of 3-4 cc. The oxygen flow rate was 
maintained at 1-2 L minute and 1- 2% isoflurane was continued for 
maintenance of anaesthesia. The previously sited nose cone was removed 
and the tracheostomy cannula was secured with a 5.0 silk suture.  
 
FIGURE	2-1– TRACHEAL INTUBATION 
 
2.2.3. Median Sternotomy 
A vertical midline skin incision was made over the sternum and xiphoid 
process. The xiphoid was excised and the diaphragm dissected free from its 
attachment to the sternum and costal cartilages. The lower end of the 
sternum was retracted upwards to visualise the heart and the lungs. The 
thymus and mediastinal fat was bluntly separated from the internal surface 
of the sternum and anterior chest wall to which it is often adherent. The 
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sternum was then divided with electrocautery (Geiger Therma Cauterizer) 
with caution to avoid the right and left internal thoracic arteries. The sternum 
was then retracted using a miniature finiochietto retractor (Fine Science 
Tools, USA) to expose the heart, lungs and great vessels (Figure 2.2). To 
facilitate visualisation of the heart and great vessels the thymus can be 
removed with electrocautery.  Alternatively, this step can be avoided if 
exposure of the heart and lungs is not desired. 
 
2.2.4. Arterial cannulation for extracorporeal membrane 
oxygenation (ECMO) inflow 
The animal was administered 100 units of heparin (0.1 ml of 1000 units/ml 
preparation). The femoral artery had already been dissected during the 
preparation for venous cannulation of the femoral vein. The distal end of the 
femoral artery was ligated using a 6.0 silk suture. This ligature was used to 
retract the artery distally to optimise its exposure for cannulation. A small 
haemostatic clamp was applied as proximally as possible to occlude the 
femoral artery. 4.0 mm tygon tubing was connected to a 24 gauge angiocath 
cannula with a three-way stopcock at the proximal end. This assembly 
constituted the femoral arterial catheter and served as the inflow route for 
our ECMO circuit. The apparatus was then primed with normal saline to 
evacuate air. The three-way stopcock was positioned such that it occluded 
the proximal end of the cannula to avoid loss of priming fluid. A small 
arteriotomy was made at the distal end of the femoral artery. Forceps were 
used to gently dilate the arteriotomy site and the angiocath cannula was 
advanced into the femoral artery. Approximately 5 mm of the length of the 
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cannula was advanced into the femoral artery. The cannula was secured 
with two 5.0 nylon ligatures to compress the vessel against the internal 
cannula. The clamp previously placed on the femoral artery was removed, a 
pulsatation was then observed in the column of blood within the cannula 
confirming adequate positioning. The arterial clamp is then reapplied to the 
artery to prevent drainage of arterial blood into the cannula, which may 
precipitate hemodynamic instability. The animal was then rotated 180 
degrees such that the head was positioned closest to the operator.  
 
Figure 2.2 below shows the animal taped down to the operating mat with 
both femoral vein and artery cannulated. 
 
FIGURE	2-2	– FEMORAL ARTERY AND VEIN CANNULA 
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2.2.5. Insertion of pressure-volume conductance catheter 
Continuous acquisition of hemodynamic data was used to complement the 
procedure and allow for precise monitoring of arterial pressure before and 
after the experiment. The right common carotid artery was dissected starting 
in the cervical region. The vessel was separated from the vagus nerve.  If a 
median sternotomy had been performed the vessel was be dissected as far 
proximally as the aortic arch to make cannulation easier. The carotid artery 
was ligated as distally in the neck as distal as possible with a 6.0 silk suture. 
A small occlusive clamp was used to occlude the carotid artery proximal to 
the site of intended cannulation. A small arteriotomy was made in the artery 
distally using microsurgical scissors. A 1.4 Fr Millar ultra-miniature pressure-
volume (PV) conductance catheter (SPR 839, Millar Instruments, Houston, 
Texas) was inserted into the vessel through this incision and secured with a 
6.0 silk ligature. The vascular clamp was removed and the catheter was 
advanced retrograde into the aortic arch. The catheter was connected to a 
Millar Ultra pressure volume system (Millar instruments, Houston) for the 
acquisition of hemodynamic data. Hemodynamic data was viewed and 
analysed using Labchart 7 software (ADI instruments). Arterial blood 
pressure was measured directly from the ascending aorta. After acquisition 
of baseline haemodynamic data the PV catheter was advance into the LV by 
crossing the aortic valve. The catheter was manipulated until both the 
pressure and volume signals were optimised. Baseline PV data from the LV 
was acquired. The IVC was occluded in order to change the pre-load of the 
heart, this allows for generation of a series of PV loops for calculation of load 
independent contractility and compliance. After baseline PV loops were 
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acquired the catheter was withdrawn into the ascending aorta. To obtain RV 
pressure volume loops the PV catheter was inserted in a retrograde fashion 
into the RV through a stab incision in the pulmonary artery. 
2.2.6. PV conductance catheter calibration 
The volume conductance signal is non-calibrated and needs to be converted 
to absolute volumes if actual volume status is to be ascertained.  
 
The calibration procedure involves the use of a cuvette comprised of 
cylinders of known volumes. Using the calibration cuvette a blood sample 
from the animal was obtained in order to convert arbitrarily assigned relative 
volume units (RVU) to true volume units such as µl. The cuvette is 
comprised of a number of cylinders of known and increasing volumes. 
Freshly drawn blood from a heparinised animal was used to fill the cylinders. 
The conductance changes were noted in the volume channel on labchart 
and the RVU value for each cylinder was recorded. The conductance 
outputs obtained from each of the cylinders can be correlated with the 
known cylinder volumes to develop a calibration equation for conversion of 
RVUs into true volume units.  
 
2.2.7. Jugular venous cannulation 
A 20 G angiocath cannula was used as the venous cannula, this cannula 
required modification with two extra holes at its distal end to aid with venous 
drainage. Prior to cannulation the cannula was attached to a length of 
4.0mm tygon tubing with a three way tap at the end and was primed with 
normal saline to evacuate the air. 
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The right jugular vein was dissected circumferentially in the cervical region to 
allowing the passage of a 6-0 ligature beneath the vessel.  The vessel was 
ligated as distal as possible such that there was a sufficient length proximally 
above the clavicle to allow for cannulation.  The distal ligature was retracted 
to facilitated exposure of the jugular vein.  A small haemostatic clamp was 
applied proximally to occlude the jugular vein.  A small venotomy was made 
at the distal end of the jugular vein.  Forceps were used to gently dilate the 
venotomy site and the angiocath cannula was advanced into the jugular 
vein.  A ligature was loosely placed around the jugular vein to secure the 
cannula, following which the clamp occluding the vessel was removed.  The 
cannula was then advanced under direct vision into the superior vena cava. 
The cannula should be held with an angulation of approximately 15 degrees 
from the anterior surface of the clavicle. 
 
Figure 2.3 below demonstrates internal jugular cannulation with the 20G 
angiocath, PV conductance catheter inserted into the right carotid artery, in 
addition to the cannulation of the femoral vessels. 
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FIGURE	2-3 - IV ACCESS AND MONITORING CANNULATIONS 
 
2.2.8. ECMO circuit 
A micro-peristaltic pump (Digital Reglo pump model 1329, Ismatec Ltd, 
Glattbrugg, Switzerland) was utilised for propulsion within the circuit. The 
pump was attached to the ECMO circuit through a customised pump 
cassette (Ismatec Ltd, Glattbrugg, Switzerland). 4.0 mm Tygon tubing was 
used as tubing for the circuit. A miniature oxygenator device (Living systems 
inc., Vermont, U.S.A.) was secured into the arterial limb of the circuit (Figure 
2.4). Heparinised saline (20 units/ml) was used to prime the oxygenator and 
the tubing evacuating all the air. The prime volume of the circuit was 5mls, 
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this affects the haematocrit and therefore a different calibration for the 
conductance catheter is used. 
	
FIGURE	2-4	– MEMBRANE OXYGENATOR SHOWING DEOXYGENATED BLOOD AT THE INFLOW 
END, SIDE PORT FOR ATTACHMENT OF OXYGEN AND OXYGENATED BLOOD AT THE OUT-FLOW 
END. 
 
Figure 2.5 below shows a schematic of the ECMO circuit  
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FIGURE	2-5	-	FIGURE 2.5: SCHEMATIC OF ECMO CIRCUIT 
 
 
The pump and associated apparatus were positioned to the right of the 
animal as show in figure 2.6. A 10 ml syringe filled with normal saline was 
attached to the circuit and acted as reservoir. Infusion of volume from the 
syringe was used to support ECMO perfusion and maintain flow if there was 
a reduction in venous drainage. A Y-circuit was constructed to allow for 
oxygen to be directed into both the oxygenator and also the ventilator. Using 
this configuration the route of oxygenation of the animal could be alternated 
between mechanical ventilation of the lungs via the tracheostomy and 
ECMO. 
 
O2
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FIGURE	2-6  - SETUP OF THE ECMO CIRCUIT 
 
2.2.9. Cardiac arrest and cessation of circulation  
After cannulation for ECMO a further 400 units of heparin was administered 
intravenously. Both common carotid arteries had previously been ligated, 
thereby preventing cerebral perfusion and ensuring that inhalational 
anaesthesia could be discontinued without recovery of consciousness. 
Sudden cardiac arrest was initiated either by cessation of ventilation or by 
rapid ventricular pacing to induce ventricular fibrillation. For hypoxic arrest 
the tracheal cannula was removed from the tracheostomy site and a clamp 
was used to occlude the trachea. Hypoxia ensued and was followed by 
onset of hemodynamic instability. Tracheal occlusion culminated in hypoxic 
cardiac arrest. Ventricular fibrillation was induced by rapid ventricular pacing. 
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With both techniques the haemodynamics and arterial blood pressure were 
continuously monitored using the previously sited PV conductance catheter 
in the ascending aorta. The time from tracheal occlusion or ventricular 
fibrillation to cardiac arrest was documented. Following circulatory arrest the 
animal was subjected to a period of warm ischemia. The prevailing core 
body temperature during this period was maintained between 35 - 37 oC. 
The duration of warm ischemia observed was 15 minutes. We observed no 
differences between these 2 modes of cardiac arrest. 
 
2.2.10. Cardiac resuscitation using ECMO  
After the warm ischemic period had elapsed ECMO was commenced. 
Deoxygenated venous blood was drained via the jugular venous cannula 
and pumped through the membrane oxygenator. Oxygenated blood was 
then returned to the animal via the femoral arterial cannula. Pump flow rate 
was gradually increased until the perfusion pressure was approximately 50-
60mmHg. Arterial blood samples were serially acquired for blood gas 
analysis. Acidosis was treated with intravenous administration of 8.4% 
sodium bicarbonate. Occasionally perfusion pressure needed to be 
augmented via intravenous injection of 0.1 mg of phenylephrine. 
Reperfusion of the coronary circulation was followed by cardiac reanimation 
with recovery of heartbeat, rate and rhythm. After 20 minutes of reperfusion 
and return of coordinated cardiac contraction, mechanical ventilation was 
recommenced and ECMO was discontinued. Consequently, the resuscitated 
heart was responsible for supporting the circulation. The PV conductance 
catheter was advanced into the LV via the ascending aorta. PV data was 
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acquired for measurement of load-independent contractility and compliance 
of the resuscitated LV. Temporary IVC occlusion was undertaken to reduce 
preload for the acquisition of a series of PV loops. 30 minutes after cardiac 
resuscitation satisfactory LV and RV PV loops were obtained, after which the 
conductance catheter was removed from the carotid artery or the pulmonary 
artery. The heart was excised for subsequent histological and molecular 
analysis. After excision a portion of the hearts were placed in a tissue 
freezing medium formulated with soluble glycols and resins and stored at -
80oC, the other hearts where used to isolate cardiac myocytes. The animal 
was euthanized via exsanguination and the carcass was disposed.  
 
 
2.3. RODENT MODEL OF BRAIN STEM DEATH (DBD) 
2.3.1. Ventilation and venous access 
Anaesthesia, venous access and monitoring were undertaken as detailed 
above. 
 
2.3.2. Tracheostomy and mechanical ventilation 
Tracheostomy and mechanical ventilation were established as detailed 
above 
 
2.3.3. Median Sternotomy 
Median sternotomy undertaken as described above in order to expose the 
heart and the great vessels. 
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2.3.4. Insertion of pressure-volume conductance catheter 
This was carried out as described above. LV and RV pressure-volume data 
was acquired for the measurements of load-independent ventricular 
contractility and compliance. The PV catheter was then placed into the 
ascending aorta for haemodynamic monitoring. 
 
2.3.5. Brain stem death induction 
The animal was placed in a supine position with head elevated. A skin 
incision was made over the right hemicranium to expose the periosteum of 
the skull. Using electrocautery the periosteum was dissected from the 
underlying bone. A 1.4 mm drill-bit was used to produce a burr hole in the 
right parietal bone. A 2 Fr Fogarty balloon catheter (Edwards Lifesciences, 
Irvine, California) was inserted into the cranial cavity. The balloon was then 
slowly inflated in the subdural space with 0.5 ml of sterile water over 2 
minutes.57 This manoeuvre consistently resulted in an increase in ICP with 
compression and herniation of the brain-stem. BSD was confirmed through 
observation of a hyperdynamic response with tachycardia and hypertension. 
Further confirmation of BSD was undertaken using an apnoea test. 
Administration of isoflurane was discontinued and the ventilator was 
switched off. Absence of any respiratory effort in the anaesthetised animal 
was taken as further confirmation of BSD. Two hours after the induction of 
BSD, the conductance catheter was reintroduced into the LV and RV in 
order to acquire PV loops. Arterial blood samples were removed for analysis 
of gas exchange and plasma biochemistry. The heart was excised for 
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subsequent isolation of cardiac myocytes. The animal was euthanised via 
exsanguination and the carcass was disposed.  
 
2.4. Sham experiments 
Sham experiments with the ECMO circuit running for 30 minutes in control 
animals yielded normal values in isolated cells. Control animals refer to no 
ECMO unless otherwise stated. 
 
2.5. Pharmacological reagents 
Epinephrine infusion was performed with 23 µg/kg/min for 30 minutes 
through the internal jugular vein.  
To inhibit CAMKII, 1 mg of KN93 (Sigma) or 100 µg of myristoylated-AIP 
(Calbiochem) was used.  
To inhibit PKA, 1 mg of H89 (Sigma) was raised in 1 cc of 0.9% normal 
saline and infused over 10 minutes.  
Experimental protocols were initiated 10 minutes after infusion. For 
experiments with Alda-1, 0.0324g of Alda-1 dissolved in 2ml of 
50%PEG/50%PBS and was injected intraperitoneally one hour before 
establishment of the cardiac arrest model.  
In the isolated myocyte experiments, cells were exposed to 100 nM of 
epinephrine in the extracellular solution. 
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2.6. Isolation of ventricular cardiac myocytes.  
Following each experiment adult ventricular cardiac myocytes were isolated 
from the rats based on previously published protocols.58  
Briefly, the heart was excised and retrogradely perfused at 37°C with a 
calcium free solution containing (in mM) 120 NaCl, 14.7 KCl, 0.6 KH2
 
PO4, 
0.6 Na2
 
HPO4, 1.2 MgSO4
 
-7H2O, 4.6 NaHCO3, 10 Na-HEPES, 30 taurine, 
10 2,3-butanedione monoxime, and 5.5 glucose (pH 7.0) for 4 min followed 
by an enzymatic digestion with collagenase type 2 (Worthington 
Biochemical, Lakewood, NJ) 394 U/mg. Figure 2.7 below shows the excised 
heart suspended in the Langendorff, figure 2.8 shows a close up of the 
excised heart. The digestion was initially performed in calcium free solution 
for 2 min, and CaCl2
 
was then added for a final concentration of 50 M and 
perfused for an additional 6 minutes. The heart was then removed, and the 
LV and RV were separated. Each ventricle was first cut into small pieces 
and then further digested by gently pipetting with plastic transfer pipettes for 
3–5 min. Stop buffer [calcium free solution + 12.5 mM CaCl2 + 10% bovine 
calf serum (Hyclone, Logan, UT)] was added, and the cell suspension was 
collected in a 15-ml tube and using a Sorvall RT6000B benchtop centrifuge, 
centrifuged at 30 g for 3 min. Myocytes were resuspended in stop buffer 
containing 100 mM CaCl2, allowed to rest for 2 min, and then centrifuged at 
30 g for 3 min. These steps were repeated using stop buffer with increasing 
CaCl2
 
concentrations until 1 mM was achieved.  
 
After isolation, experiments were performed with freshly isolated myocytes 
resuspended in a HEPES-buffered solution containing (in mM): 1 CaCl2, 137 
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NaCl, 5.4 KCl, 15 dextrose, 1.3 MgSO4, 1.2 NaH2PO4, and 20 HEPES (pH 
7.4). 
 
FIGURE	2-7 - LANGENDORFF APPARATUS FOR COLLAGENASE DIGESTION AND 
MYOCYTE ISOLATION 
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FIGURE	2-8	– CLOSE UP OF HEART ATTACHED TO LANGENDORFF 
 
2.7. Myocyte unloaded shortening and relaxation.  
Cell contraction properties of myocytes were evaluated with a video-based 
sarcomere spacing acquisition system (SarcLen; IonOptix, Milton, MA) as 
previously described.58 Rod-shaped ventricular cardiomyocytes with clear 
striation patterns that were quiescent when un-stimulated, but robustly and 
symmetrically twitching to field stimulation, were chosen. These cells were 
placed in a culture chamber stimulation system (Cell MicroControls, Norfolk, 
VA), mounted on an inverted microscope (Nikon TE2000U; Nikon, Melville, 
NY), and electrically stimulated with suprathreshold voltage at frequencies 
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as specified in experiments. Changes in sarcomere length were recorded, 
and further analysis was performed using IonWizard software (IonOptix). 
 
2.8. Calcium transient measurements 
Ventricular myocytes were loaded with 0.2 µM of Fluo-5f-acetoxymethyl 
ester (Molecular Probes, Eugene, OR) for 30 min, and then allowed to 
incubate in dye free HEPES-buffered saline for additional 30 min to allow for 
de-esterification of the calcium dye. Myocytes were electrically field 
stimulated at a frequency specified in experiments. Cells were excited and 
spatially averaged calcium transients were measured using a standard FITC 
cube (Chroma) using the HyperSwitch system (IonOptix). The fluorescence 
transients were normalized to ΔF/F units and characterized according to the 
following parameters as previously described59: (ΔF/F)peak; time to peak (tp 
was measured from the initiation of the rising phase of the transient), delay 
to baseline (td measured from the (ΔF/F)peak to 90% of the return to 
baseline). The dye was assumed to be at near equilibrium with the calcium 
transient. 
 
2.9. Two-Carbon Fiber Technique 
Cells were isolated, prepared, and mounted on the inverted microscope 
similar to above. A pair of micro-carbon fibers, each attached to miniature 
hydraulic manipulators (SM-28, Narishige, Tokoyo, Japan) and computer-
controlled with a piezoelectric translator (P-621.1CL, Physik Instruments, 
Karlsruhe/Palmbach, Germany) mounted on a custom made railing system 
(IonOptix, Milton, Mass), were attached to single isolated ventricular 
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myocytes robustly twitching in response to field stimulation (IonOptix, Milton, 
Mass). Figure 2.9 below shows the setup of the equipment.  Cells were 
stretched axially by the piezoelectric translator movement of the carbon 
fibers using custom software (Matlab, courtesy of Mr. P Lee). Sarcomere 
length changes were confirmed via fast Fourier transformation of sarcomere 
banding (SarcLen; IonOptix Milton, MA). Carbon fiber bending was 
measured (IonOptix, Milton, Mass) and force was calculated as by using the 
following formula: 
F = K(ΔLF - ΔLP) 
Where ΔLF is the change in distance between the two carbon fiber tips that 
are attached to the cell, and ΔLP is the change in distance between the two 
piezoelectric translators to which the carbon fibers holders are mounted. K is 
the stiffness of the carbon fiber (0.15-0.25 µN⋅µm-1).60 Individual diastolic and 
systolic cell results were plotted and fitted using a linear regression model 
(Origin, Northhampton, MA) to give both end-systolic and end-diastolic 
length-tension relationships (ESLTR and EDLTR, respectively). Data were 
normalised to the starting systolic force or as the Frank-Starling gain to 
eliminate the spring constant.61 
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FIGURE	2-9- INVERTED MICROSCOPE WITH A PIEZOELECTRIC TRANSLATOR MOUNTED 
ON A CUSTOM MADE RAILING SYSTEM 
 
2.10. Western blotting 
Left ventricles were homogenized over ice in mannitol-sucrose lysis buffer 
containing 1:300 dilutions of phosphatase inhibitor/protease inhibitor 
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cocktails 2 and 3 (Sigma-Aldrich) and 1% Triton-X v/v. Protein content was 
quantified using a Bradford assay (Bio-Rad). Protein separation was done in 
10% SDS-PAGE gels transferred to Immobilon-P (Millipore). Blots were 
probed respectively with 1:1000 CAMKII G69 clone (Milllipore), 1:500 
Phospho-CAMKII (Cell Signaling), and 1:1000 sarcomeric actin (Sigma-
Aldrich). All secondary antibodies (anti-mouse HRP and anti-rabbit HRP) 
were obtained from GE Amersham. CAMKII and phospho-CAMKII were 
visualised using SuperSignal femto-ECL (Pierce). Sarcomeric actin was 
visualised using Amersham ECL. Image capture was made with Bio-RAD 
ChemiDoc XRS imaging. Quantification of densitometry was done with 
ImageJ v1.46n. 
 
2.11. In Situ Optical Mapping of Voltage and Calcium in 
the Heart  
 
In an attempt to visualize CICR in-vivo and map the voltage, we made the 
following imaging system. Our system as shown in the schematic below 
(figure 2.10) was constructed from readily-available optical filters, lenses, 
LEDs, electronics, and a single high-speed, electron-multiplied charge-
coupled-device (EMCCD) camera (Photo-metrics, Tucson, AZ, USA). 
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FIGURE	 2-10	 - SCHEMATIC OUTLINE OF THE IMAGING SYSTEM, HIGHLIGHTING KEY 
COMPONENTS. SINCE ONLY ONE CAMERA IS USED, THE SYSTEM REQUIRES NO CHALLENGING 
OPTICAL ALIGNMENT. EXCITATION SOURCES EX1: RED LED WITH A 640610 NM FILTER (F1), 
EX2: GREEN LED WITH A 540612.5 NM FILTER (F2). 
 
We measured Vm using di-4- ANBDQPQ (Berlin Center for Cell Analysis and 
Modelling, University of Connecticut, USA) and [Ca2+]i
 
using rhod-2(AM) 
(Molecular Probes, Eugene, OR, USA). Di-4-ANBDQPQ was excited with 
Ex1: LED CBT-90-R (peak power output 32 W; peak wavelength 628 nm; 
Luminus Devices, Billerica, MA, USA) using excitation filter D640/206 
(Chroma Technology, Bellows Falls, VT, USA). Rhod-2(AM) was excited 
with Ex2: LED CBT-90-G (peak power output 58 W; peak wavelength 524 
nm; Luminus Devices) with excitation filter D540/256 (Chroma Technology). 
Light from the LEDs was collimated with plano-convex lenses (LA1951; 
Thorlabs, Newton, NJ, USA). Fluorescence emission from dye-loaded hearts 
was passed through custom-made multi-band emission filter F3, available 
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from Chroma (ET585/50-800/ 200 m; Chroma Technology), with high-
percentage transmission spectra for both emission bands (~560–610 nm 
and ≥700 nm), and collected with a fast camera-suitable lens (f/# 0.95; DO-
2595; Navitar). Fluorescence images were taken with a high-speed EMCCD 
camera (CascadeH 128+ or EvolveTM 128, Photometrics) running at 510 
(Cascade) or 530 (Evolve) frames-per-second (both at 128 X 128 pixels). 
Figure 2.11 shows the experimental setup with the camera in place over the 
heart. 
	
FIGURE	2-11 - EVOLVE (PHOTOMETRIC) CAMERA SHOWN IN THE EXPERIMENTAL SET UP, 
OVER THE RAT THAT IS ON ECMO 
 
 
A microcontroller-based interface was implemented (figure 2.12) to 
synchronise excitation light switching with EMCCD camera frame exposure 
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periods (in our experiments, the camera ran off its internal clock; i.e. the 
camera was master and the LEDs were slaves). LEDs were controlled with a 
custom-built high-power LED driver circuit that enables illumination power to 
be tuned, and light output to be switched in the kHz range. An eight 
processor microcontroller (Propeller chip; Parallax, Rocklin, CA, USA) was 
used to control and coordinate all major components of the set-up. Control 
software for time-critical tasks was written in the microcontroller’s assembly 
language, to ensure a time resolution of 50 ns. Communication with a 
standard desktop computer was implemented via a USB interface module 
(UM245R; Future Technology Devices International, Glasgow, UK). Custom 
software, written in MATLAB (The MathWorks, Natick, MA) was used to 
design experiments, to communicate with the microcontroller, and to perform 
optical mapping image processing. All electronic components used to build 
the micro-controller-based interface were acquired from major electronic 
components distributors (e.g. Digi-Key, Thief River Falls, MN, USA).  
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FIGURE	 2-12– MICROCONTROLLER, COMPUTER RUNNING MATLAB, LED DRIVER 
CIRCUIT 
 
 
Male Sprague-Dawley rats (250–300g) were anesthetised with 1–2% 
isoflurane in oxygen as described before. Rats were maintained at 37oC and 
depth of anesthesia was monitored throughout according to standard 
protocols (APLAC, Stanford University). Tracheotomy was established with a 
14-gauge cannula and the animal was ventilated at a pressure support of 15 
mmHg at 60 breaths per minute (Kent Scientific, San Diego, CA, USA). A 
standard sternotomy was then performed. The right femoral artery (FA), 
external jugular vein (EJV), and ascending aorta (AA), via the carotid artery 
(CA), were cannulated with polyethylene tubing. Heparin (1,000 units/kg, 
Sigma-Aldrich) was administered intra-venously. A 1.4 Fr conductance 
catheter (Millar Instruments, Houston, Texas, USA) was introduced via the 
esophagus to provide an ECG lead. Blood pressure was monitored with a 
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pressure transducer (Hugo Sachs Electrical, March- Hugstetten, Germany) 
attached to the side-port of the FA cannula. For experiments with ventricular 
pacing, a pacing stimulator (Millar Instruments) was placed on the left 
ventricular epicardial apex. Dyes were loaded by direct aortic root injection, 
during loading of voltage dye di-4-ANBDQPQ  we found no appreciable 
differences in these ECG traces or MAP.  Rhod-2(AM) loading required 
ECMO support, as the [Ca2+]i dye could lead to asystolic arrest during initial 
injection, with subsequent beating recoverable with circulatory support 
(which was always needed for calcium dye experiments). For select 
experiments as specified in the result, an ECMO circuit was used to maintain 
a mean coronary perfusion pressure of 60 mmHg (figure 2.13A). The ECMO 
circuit as described in detail above involved a micro-peristaltic pump (Digital 
Reglo Pump Model 1329, Ismatec Ltd., Wertheim- Mondfeld, Germany), in 
line with the tubing and a miniature membrane oxygenator (Living Systems 
Inc St. Albans, Vermont, USA), and in parallel to a venous reservoir. The 
circuit was primed with 5 mL of heparinised saline (20 units/mL) to remove 
all air. The ECMO circuit was attached in series to the EJV and FA, and run 
in a retrograde manner when used.  
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FIGURE	2-13	 -	 (A) A SCHEMATIC OF THE RAT ECMO CIRCUIT BASED ON A STANDARD PUMP 
CIRCUIT (EJV: RIGHT EXTERNAL JUGULAR VEIN CATHETER, VR: VENOUS RESERVOIR, RP: 
ROLLER PUMP, MO: MINIATURE MEMBRANE OXYGENATOR, FA: RIGHT FEMORAL ARTERY 
CATHETER, AA: ASCENDING AORTA CATHETER VIA RIGHT CAROTID ARTERY). IN 
CARDIOPULMONARY BYPASS (CPB) MODE, BLOOD IS PUMPED FROM THE EJV THROUGH THE 
MO TO THE FA, DEPICTED BY ARROWS IN THE FIGURE. DYE IS INJECTED THROUGH THE AA 
CATHETER. (B) WHOLE-ANIMAL VIEW OF THE PREPARATION. (C) ZOOMED-IN VIEW OF THE 
OPEN CHEST, WITH THE HEART IN CLEAR VIEW (EL: ESOPHAGEAL ECG LEAD, ET: 
ENDOTRACHEAL TUBE). (D) AN EXAMPLE OF RVP AT 12 HZ TO DROP BLOOD PRESSURE 
(BP; RED TRACE), AFTER WHICH DYE WAS INJECTED VIA THE AORTIC ROOT. THE BP 
RECOVERED SOON AFTER CESSATION OF PACING. IMMEDIATELY AFTER LOADING AS SHOWN 
HERE, THE BP INCREASED REFLECTING THE FRANK-STARLING EFFECT OF PROLONGED 
LOADING. THE ACCOMPANYING ECG (BLACK TRACE) IS ALSO SHOWN. (E) ZOOMED-IN VIEW 
OF THE HEART IMMEDIATELY AFTER RHOD-2(AM) INJECTION DEMONSTRATING A 
FLUORESCENT CORONARY ANGIOGRAM. 
 
 
Figures 2.13B and 2.13C show photographs of the imaging camera view of 
the preparation. Traditional coronary catheterisation has already been 
employed to load voltage dyes in larger animals without complications,51 but 
was impractical in the rat. Therefore, dyes were injected into the ascending 
aorta via the carotid artery and towards the coronary circulation. To 
accomplish this, blood pressure had to be reduced to allow sufficient 
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coronary perfusion with the dyes. As shown in Figure 2.13D and 2.13E, 
blood pressure was reduced through combination of rapid ventricular pacing 
(RVP, 12 Hz) to impair ventricular diastolic filling, thereby reducing stroke 
volume sufficiently to decrease arterial blood pressure, similarly to what is 
done clinically during stent-valve implantation.62 Once blood pressure was 
reduced sufficiently to decrease resistance to injection (Figure 2.13D), the 
aorta was temporarily cross-clamped, and dye was injected through the 
carotid artery catheter, mimicking the clinical aortic root injections of contrast 
agents.62 Figure 2.13E shows a still image during dye loading (rapidly 
thereafter the dye leaves the vascular space because of its amphiphilic 
properties). We found that RVP and cross-clamp periods not exceeding 10 
seconds were sufficient to permit dye loading through the coronary 
circulation. Blebbistatin was added to the circulation during final imaging to 
reduce wall motion.63 When blebbistatin was used, cardiopulmonary bypass 
was used to preserve coronary perfusion.  
 
2.12. Image processing  	
Custom MATLAB software was used to perform optical map image 
processing. Signals were filtered (in time) with local regression using 
weighted linear least squares and a 1st degree polynomial model (MATLAB’s 
built-in smooth function) and images were filtered using 2D median filtering 
(MATLAB’s built-in medfilt2 function).  
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2.13. Statistics  
Pairwise comparisons were made using Student’s t-test. One-way ANOVA 
was used in the event of multiple groups. Post hoc testing was carried out 
according to the method of Bonferroni. Exact P values are stated in most 
cases. All data is presented in the text as mean ± standard error of the 
mean.  
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CHAPTER 3. RESULTS 
 
3.1. RODENT MODEL OF DONATION AFTER CIRCULATORY 
DEATH 
Using the miniature ECMO circuit for reperfusion of the DCD heart, cardiac 
function was evaluated after reperfusion of the rat heart following circulatory 
arrest and warm ischemia. In human DCDs inotropic and ventilatory support 
are withdrawn. Cardiac arrest subsequently occurs due to asphyxiation and 
hypoxia after the donor is extubated. In order to simulate the hypoxic injury 
that produces cardiac arrest in the human DCD, the trachea was clamped in 
the rat model to produce asphyxiation and cardiac arrest. Tracheal occlusion 
was followed by progressive hypotension and bradycardia. This preceded 
cardiac arrest which occurred 5.4 +/- 2.8 minutes after tracheal occlusion. 
Following circulatory arrest and 15 minutes of warm ischemia the animal 
was reperfused with normothermic oxygenated blood using a miniature 
ECMO circuit. Reperfusion led to recovery of cardiac function with re-
establishment of normal cardiac rhythm. After 30 minutes of reperfusion, the 
supportive extracorporeal circulation was weaned to allow the resuscitated 
heart to independently support the animal’s circulation. Schematic of our 
ECMO circuit are depicted in figure 3.1. 
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FIGURE	3-1	– MINIATURE ECMO CIRCUIT 
 
 
Haemodynamic changes observed in the rat DCD are shown in figure 3.2 
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FIGURE	3-2	– ARTERIAL BLOOD PRESSURE CHANGES FOLLOWING CARDIAC ARREST 
AND THEN REPERFUSION WITH ECMO 
 
3.2. RODENT MODEL OF DONATION AFTER BRAIN-STEM 
DEATH 
Subdural balloon inflation was followed by a hyperdynamic response with 
marked hypertension and tachycardia, leading to a rise in ICP with 
consequent coning and transtentorial herniation of the brain-stem. The 
hemodynamic response to BSD is depicted in figure 3.3.  
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FIGURE	3-3	– BLOOD PRESSURE CHANGES DURING SUBDURAL BALLOON INFLATION AND BSD 
 
With balloon inflation there was a sharp rise in arterial blood pressure with 
peak systolic pressures nearing 250 mmHg. This hypertensive crisis was 
then followed by a gradual decline in blood pressure back towards base line. 
In 3 rats this decline didn’t stop and blood pressure fell to zero within 5 
minutes. 
In the rats that survived, data was collected at 2 hours after balloon inflation. 
Hypertension following balloon inflation was accompanied with an average 
rise in heart rate of almost 50 bpm. The hemodynamic response to BSD is 
secondary to a dramatic increase in circulating plasma catecholamines.64 
Exposure of the heart to markedly elevated catecholamine concentrations 
has been associated with cardiac dysfunction and a decline in hemodynamic 
performance.65 There is uncertainty as to whether the cardiac dysfunction 
observed after BSD is due to primary impairment of LV contractility or 
secondary to abnormal loading conditions of the heart.66,67 
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3.3. PV analysis of DCD vs DBD 	
Pressure volume hemodynamic measurements were taken from both LV 
and RV before and after cardiac arrest and after DBD, representative PV 
loops are shown in figures 3.4 A-C and 3.5 A-C. The LV and RV 
measurements were not necessarily taken from the same animal.  LV 
comprised of 16 control, 5 DBD & 7 DCD, RV comprised of 11 control, 12 
DBD & 14 DCD. The data is shown in figure 3.6 below. 
 
EDPVR exponentials did not well fit the data in the post-arrest samples 
therefore Tau(τ) was used to describe the lusitropic properties of the hearts. 
Analysis showed no significant change between the control group and DBD 
group when looking at ESPVR, PRSW and Tau. However, when looking at 
the measure of Contractility Index there was an increase in the DBD group. 
The DBD experiment was difficult to replicate. Many of the experiments 
failed after inducing brain death due to the animal not surviving the insult, 
while the ones that did survive may not have had a sufficient insult and 
therefore the increase in CI may be a result of increased circulating 
catacolamines with their adrenergic effects. There was, however, a 
significant decrement in contraction and relaxation following DCD (ESPVR -
44%; CI-48%; PRSW -31%; τ +500%). Together, these data demonstrate 
the phenomenon of post cardiac arrest myocardial dysfunction (PMAD) 
following DCD. There was no difference seen when directly comparing 
changes in LV and RV function between control/DBD/DCD, this was 
reassuring to see as LV and RV have different embryological origins and 
often the first sign of organ failure post transplantation is RV dysfunction. 
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FIGURE	3-4 - REPRESENTATIVE PV LOOPS FROM THE LEFT VENTRICLE: A – 
CONTROL, B – DCD & C DBD. RED LINES DEMONSTRATING ESPVR AND EDPVR 
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FIGURE	3-5	– REPRESENTATIVE PV LOOPS FROM THE RIGHT VENTRICLE: A – 
CONTROL, B – DCD & C DBD. RED LINES DEMONSTRATING ESPVR AND BLUE 
LINE EDPVR 
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FIGURE	3-6	– SUMMARY DATA FOR BOTH LV(A-D IN BLACK) AND RV(E-H IN RED). A, 
SUMMARY DATA FOR LV ESPVR FOR CONTROL, DBD AND DCD. B, SUMMARY DATA FOR 
LV PRSW FOR CONTROL, DBD AND DCD. C, LV SUMMARY DATA FOR CI (MMHG/µL)*S FOR 
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CONTROL, DBD AND DCD. D, SUMMARY DATA FOR LV TAU FOR CONTROL, DBD AND DCD. 
E, SUMMARY DATA FOR RV ESPVR FOR CONTROL, DBD AND DCD. F, SUMMARY DATA FOR 
RV PRSW FOR CONTROL, DBD AND DCD. G, RV SUMMARY DATA FOR CI (MMHG/µL)*S 
FOR CONTROL, DBD AND DCD. H, SUMMARY DATA FOR RV TAU FOR CONTROL, DBD AND 
DCD. P VALUES IN GRAPHS ARE WITH RESPECT TO CONTROL USING POST HOC ANALYSIS. 
LV: CONTROL N=16, DBD N=5 & DCD N=7. RV: CONTROL N=11, DBD N=12 & DCD N=14 
 
3.4. Cellular Contractility in Post-myocardial arrest 
dysfunction 
To investigate cell function directly, we first examined unloaded sarcomere 
shortening (%SL) in isolated adult cells from LV control and PMAD hearts. In 
cells paced at 1 Hz steady state, the %SL for control and PMAD cells was 
13±0.3 vs 10±0.7, a 23% decrease in the %SL in unloaded cells (p=3e-4, 
n=142 cells from 12 animals and 186 cells from 10 animals for control and 
PMAD, respectively). Likewise, we found that the peak velocity of 
contraction (vc) was 4.3±0.2 vs 2.6±0.1 while the peak velocity of relaxation 
(vr) was 2.5±0.1 vs 2.0±0.1 1 µ/ms in control vs PMAD cells (same n as 
above, p=2e-14, p=5.2e-4; data not shown).  
To validate the unloaded shortening data, and provide further insights into 
contractile dysfunction in PMAD, we investigated single cell force and 
contractility in PMAD and control left ventricular cells using the two-carbon 
fiber stretch technique.60  Figure 3.7 A shows a single isolated adult left 
ventricular myocyte before and after a twitch in response to electrical 
stimulation, showing the carbon fiber bending.  Figure 3.7 B shows the 
stepwise stretch protocol, the cellular Frank-Starling effect. Figure 3.7 C 
shows carbon fiber bending for the same stretched cell which is proportional 
to force.60 Corresponding to the derivation by regression of load 
‘independent’ values in vivo, the ESTLR and EDTLR are defined in single 
cells as the slopes of the linear regressions of systolic and diastolic force 
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plotted against sarcomere length obtained from plots shown in Figure 3.7 
B,C. These two relationships are shown in Figure 3.7 D for the control fiber 
from Figures 3.7 B and C. These experiments were repeated in cells from 
PMAD animals (Figure 3.7 E). We found both the ESLTR and EDLTR to be 
depressed in the PMAD cells. In Table 3.1, pooled analysis of the slopes of 
the ESTLR and EDTLR for both control and PMAD cells are shown. For this 
pooled analysis, all ES and ED force measurements were normalized to the 
baseline (un-stretched) systolic force in order to remove any effect of 
variability in carbon fiber stiffness (variability in spring constant), and then 
linearly fit. As illustrated in Table 3.1, the ESLTR and EDLTR were 60% and 
36% depressed in PMAD cells, respectively, compared with that of controls 
(p<0.05). In addition, we calculated the Frank-Starling gain by dividing the 
active force by the passive force at each stretched length, also a 
dimensionless index which describes PRSW at the single cell level. 61 In 
Figure 3.7 F, we therefore plot PRSWcell vs afterloadcell. As can be 
appreciated, this cellular data recapitulates length-tension curves obtain with 
PV loops, and suggests that contractility is significantly depressed in PMAD. 
Figure 3.7 G shows the active force frequency relationship (FFR) for both 
control and PMAD cells under no passive stretch (baseline sarcomere 
length) as measured by carbon fiber bending with twitch, demonstrating that 
the FFR is depressed in PMAD cells at all frequencies investigated.  
 
 
	 58	
 
FIGURE	3-7 - IN VIVO AND ISOLATED CELL LOAD DEPENDENT PARAMETERS IN CONTROL AND 
CARDIAC ARREST. A. ISOLATED TWITCHING MYOCYTE (CONTRACTED STATE) BEFORE (TOP) 
AND DURING TWITCH IN RESPONSE TO ELECTRICAL ACTIVATION DEMONSTRATING CARBON 
FIBER BENDING.  B THE SARCOMERE LENGTH (µM) IN RESPONSE TO 1 HZ PACING VS TIME AS 
CF STRETCH IS APPLIED TO THREE DIFFERENT ENDPOINT LENGTHS DEMONSTRATES THE 
CELLULAR FRANK-STARLING EFFECT. BETWEEN EACH STEP, THE CFS ARE RETURNED TO 
BASELINE. EACH STRETCH PRODUCES INCREASED SARCOMERE LENGTH CHANGE. C. 
CARBON FIBER BENDING (CFB) (PROPORTIONAL TO FORCE) VS TIME DEMONSTRATING THE 
INCREASE IN BOTH DIASTOLIC (PASSIVE) AND SYSTOLIC (ACTIVE) SINGLE CELL FORCE, 
RESPECTIVELY. D. STRETCH INDUCED PEAK SYSTOLIC (OPEN SQUARES) AND BASELINE 
DIASTOLIC (FILLED SQUARES) TENSION FROM A CONTROL CELL.  THE LINEAR FITS TO THE 
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DATA REPRESENT THE EDLTR (BLACK LINE) AND ESLTR (GRAY LINE). IN THIS CASE, THE 
ESLTR WAS 22 µN/µM (R2=0.96), AND THE EDLTR WAS 6.6 µN/µM (R2=0.95). E. 
STRETCH INDUCED PEAK SYSTOLIC (OPEN SQUARES) AND BASELINE DIASTOLIC (FILLED 
SQUARES) TENSION FROM A PMAD CELL. IN THIS CASE, THE ESLTR WAS 11 µN/µM 
(R2=0.92), AND THE EDLTR WAS 6 µN/µM (R2=0.98).  F. PRSWCELL VS AFTERLOADCELL 
FORCE FOR CONTROL (OPEN SQUARES) AND PMAD (FILLED SQUARES), N= 8 CELLS FROM 3 
HEARTS AND 8 CELLS FROM 2 HEARTS FOR CONTROL AND PMAD, RESPECTIVELY. 
EXPONENTIAL FITS TO THE DATA WERE DONE USING THE EQUATION FSG= Y0+A1E^(-X/T1). 
FOR CONTROL AND PMAD, RESPECTIVELY, Y0, A1, T1 WERE: 0.94 AND 1.47, 9.5 AND 2.7, 
0.78 S AND 0.54 S. R2 WERE 0.96 AND 0.92. N= 8 CELLS FROM 3 HEARTS AND 8 CELLS 
FROM 2 HEARTS FOR CONTROL AND PMAD, RESPECTIVELY. G. FORCE FREQUENCY 
RELATIONSHIP (FFR) FOR POOLED BSF (µM) VS PACING FREQUENCY FOR CONTROL (BLACK 
SQUARES) AND PMAD (OPEN SQUARES) PLOTTED WITH SE, N= 8 CELLS FROM 3 HEARTS 
AND 8 CELLS FROM 2 HEARTS FOR CONTROL AND PMAD, RESPECTIVELY. 
 
Table 3.1 – In Vivo and Isolated Cell 
 Control PMAD (P Value) 
ESPVR (mmHg/µl) 1.0±0.10 0.5±0.1 (0.02) 
PRSW (mmHg) 58±8 30±6 (0.02) 
CI (mmHg/µl)*s 93±6 64±6 (0.005) 
τ (ms) 12±3 45±6 (7e-11) 
ESLTR (au) 84±11 34±6 (0.04) 
EDLTR (au) 44±6 28±6 (0.02) 
Peak PRSWcell (au) 8±2 3.0±1 (0.006) 
TABLE	3.	1	- IN VIVO AND ISOLATED CELL PARAMETERS: AU INDICATES ARBITRARY UNITS; CI, 
CONTRACTILITY INDEX; EDLTR, END- DIASTOLIC LENGTH-TENSION RELATIONSHIP; ESLTR, 
END-SYSTOLIC LENGTH-TENSION RELATIONSHIP; ESPVR, END-SYSTOLIC PRESSURE-VOLUME 
RELATIONSHIP; PMAD, POST–MYOCARDIAL ARREST DYSFUNCTION; PRSW, PRELOAD 
RECRUITABLE STROKE WORK; AND Τ, ISOVOLUMIC RELAXATION CONSTANT. CONTROL N=136 
CELLS FROM 11 ANIMALS, PMAD N=164 CELLS FROM 12 ANIMALS.	
 
 
3.5. Calcium induced calcium release 
Previous reports examining ischemia–reperfusion using higher affinity 
calcium indicators37 have found little change in calcium induced calcium 
release. Here, we used the lower affinity calcium indicator Fluo-5f because 
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rapid calcium transients are subject to dye kinetic filtering which can mask 
disease processes.59 In Figure 3.8 A, a single sweep of a steady-state 
pacing train is shown for a PMAD and control cell. Consistent with an early 
report in post-ischemic myocardium,41 we found that post arrest cells display 
markedly enhanced peak calcium transients. In pooled analysis, as shown in 
Figure 3.8 B, a significant 290% increased CICR amplitude was present. 
∆F/Fpeak from control (n=90 cells from 10 animals) and PMAD (n=123 cells 
from 12 animals) was 90±7 and 272±13, respectively (p=2e-29). We found 
no difference in the time to peak (tp) of the calcium transient (52±4 and 
46±10 ms, p=0.11, same n as above). The time to decay (td) of the CICR in 
PMAD was significantly prolonged (340± 9 vs 456± 9, p=4e-15), as was the 
time constant of decay (τ) (152±5 vs 216±7 ms, p=7e-10). Because this 
augmented CICR was present in isolated cells long after in vivo cardiac 
arrest, we labelled this as cardiac calcium “memory”. This calcium cardiac 
memory was able to generate a spontaneous delayed increase in the 
calcium transient, the cellular surrogate of delayed after depolarisations as 
shown in Figure 3.8 C (top panel), and these delayed after depolarisations 
were capable of competing for the paced rhythm generating the cellular 
surrogate of triggered ventricular activity as well (Figure 3.8 C lower panel). 
Activity such as this was never seen in control cells.  
To test whether higher affinity dyes used in prior experiments32 might have 
masked these increases in CICR, we repeated experiments using a high 
affinity version calcium indicator, Fluo-4. We found that Fluo-4 filtered the 
signal substantially, dramatically reducing unloaded contractility and 
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minimizing the difference between control and post cardiac arrest (Figure 
3.9).  
 
3.6. Cardiac calcium memory is precipitated in vivo and 
mediated by catecholamines  
In addition to the use of lower affinity calcium dyes, another important 
difference in the current report is our use of an in vivo model. We 
hypothesized that the neurohormonal axis may be important to ischemia 
reperfusion and to compare our data directly, we isolated cells from an 
ischemia-reperfusion Langendorff-preparation. We found that in isolated 
cells from these Langendorff “resuscitated” hearts sarcomeric shortening 
was minimally depressed and CICR was no different than controls (Figure 
3.8 B, 15 minute arrest period). 
 
We hypothesized that catecholaminergic activation was the key component 
promoting calcium cardiac memory in vivo. To test this possibility, in an 
otherwise stable ventilated animal, we infused epinephrine 23 µg/kg/min 
intravenously for 30 minutes. Infusion induced a typical adrenergic response 
and when turned off prior to cell isolation, the blood pressure and heart rate 
returned to normal (blood pH was also normal). We found a pronounced 
increase in CICR to a similar degree to that seen post cardiac arrest 
(Figures 3.8 A and B). Since it is hard to determine physiologically relevant 
doses and spectrum of adrenergic activators, we explored whether calcium 
cardiac memory resulted after brain-stem herniation, a state known to induce 
an endogenous catecholamine surge. Using a fogarty balloon inserted in the 
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cranial vault, we induced brainstem herniation, noted a similar dramatic 
heart rate and blood pressure response suggestive of adrenergic activation, 
and found a similar dramatic increase in  the ∆F/Fpeak CICR of isolated 
cells (271 ± 21, n=110 cells from n=9 animals (p=2e-25 against control; 
Figure 3.8 B). We found no effect of beta-blocker administration (labetalol) 
on CICR augmentation despite a pronounced bradycardic response during 
administration. 
 
3.7. Cardiac calcium memory is dependent on CAMKII and 
ryanodine but not PKA 
A large increase in CICR in the face of reduced contractile function suggests 
a change in myofilament calcium sensitivity (Figure 3.8 F). In contrast, 
epinephrine directly added to the cell bath showed a marked increased 
contractile performance (%SL 20±0.5) associated with a more modest 
increase CICR (ΔF/F peak 141±0.53%). Since interplay between sub-acute 
and chronic beta-adrenergic signalling and CAMKII dependent pathways has 
been observed,42,68,69 we tested whether CAMKII inhibition could block 
epinephrine infusion induced or PMAD induced calcium cardiac memory. As 
shown in Figure 3.8 B, we found that administration of the CAMKII inhibitor 
AIP was able to block the amplified CICR in both cases. We found that the 
lower affinity inhibitor KN93 was able to blunt calcium cardiac memory in 
PMAD (Figure 3.8 A, B), but not our arbitrary epinephrine infusion. Because 
CAMKII activation is in part activated by calcium dependent pathways, we 
tested whether specific inhibition of CICR during sudden cardiac arrest 
would blunt calcium cardiac memory. We found that for both epinephrine 
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infusion and PMAD, ryanodine too blocked the augmented CICR (Figure 3.8 
B), suggesting that ryanodine receptor calcium release was crucial for this 
pathway. In contrast, and in agreement with our labetalol experiment, 
infusions of the PKA inhibitor H89 prior to induction of cardiac arrest did not 
prevent the increase in CICR (though this is a higher level than that seen for 
PMAD alone, we feel it is within the range seen for cardiac arrest for which a 
larger data set shows regression to the mean; Figure 3.8 B).  
We measured both %SL (Figure 3.8 f) and force (Figure 3.8 g, h) in PMAD 
hearts exposed to either CAMKII inhibition with KN93 or with ryanodine 
during the initial cardiac arrest. We found that both %SL and baseline force 
were lower under these conditions, arguing that in these live cells, the 
augmented CICR acts to support contraction.  
 
 
	 64	
 
FIGURE 3-8 – CARDIAC CALCIUM MEMORY AFTER CARDIAC ARREST  
A. EXAMPLE CICR TRANSIENTS MEASURED BY FLUO-5F IN CONTROL COMPARED AGAINST 
PMAD, AND ALSO PMAD IN WHICH ARREST WAS GENERATED IN THE PRESENCE OF KN93 
(PMAD-KN) OR RYANODINE (PMAD-RY), AS WELL AS A CONTROL ANIMAL EXPOSED TO IV 
INFUSION OF EPINEPHRINE (EPI) FOR 30 MINUTES. CELLS WERE PACED STEADILY AT 1HZ. B. 
POOLED ANALYSIS OF ∆F/FPEAK FOR ALL CONDITIONS TESTED. THE ∆F/FPEAK WAS 
SIGNIFICANTLY HIGHER IN ANIMALS EXPOSED TO EPINEPHRINE INFUSION AND CARDIAC 
ARREST. RYANODINE AND KN93 REDUCED ∆F/FPEAK TO CONTROL LEVELS IN PMAD 
VENTRICULAR MYOCYTES. WT WAS NO DIFFERENT THAN SHAM. N=90, 123, 75, 9, 11, 15, 
11, 31, 20, 51, 119, 19, 11 CELLS FOR CONTROL, PMAD, PMAD-AIP, PMAD-KN, PMAD-
RY, EPI INFUSION, CONTROL-KN93 (CNTR-KN), CONTROL RYANODINE (CNTR-RY), EPI 
INFUSION WITH RYANODINE RYANODINE (EPI-RYR), PMAD- LANGENDORFF, BRAINSTEM 
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HERNIATION (BSH), AND BSH-RYANODINE), AND PMAD-H89. CNTR-SHAM EXPERIMENTS 
DEMONSTRATED NO DIFFERENCE COMPARED WITH CONTROL. P VALUES COMPARED TO 
CONTROL FOR PMAD, EPI INFUSION, WERE 6.4E-24, 2.2E-18 (CORRECTED FOR MULTIPLE 
COMPARISONS BY BONFERRONI CORRECTION). ALL OTHER COMPARISON WERE NOT 
SIGNIFICANT. C. EXAMPLE CICR TRANSIENTS FROM TWO DIFFERENT PMAD CELLS. TOP 
PANEL SHOWS CICR IN RESPONSE TO 1HZ ELECTRICAL STIMULATION FOLLOWED DELAYED 
CALCIUM TRANSIENTS. BOTTOM PANEL SHOWS SPONTANEOUS CALCIUM TRANSIENTS 
COMPETING FOR PACED RHYTHM AT 1HZ PACING. D. EXAMPLE TRACES FOR SIMULTANEOUS 
CICR (BOTTOM, GRAY) AND CELLULAR FORCE (TOP, BLACK) MEASUREMENTS ARE SHOWN 
SHOWN FOR AN ISOLATED CELL ELECTRICALLY PACED AT 1 HZ. THE SL WAS (IN µM) 
~1.87,~1.94 AND ~2.0 AT THE SLACK LENGTH, THE FIRST, AND THE SECOND STRETCH. E. 
POOLED ANALYSIS OF VELOCITY OF CONTRACTION (VC) VS SARCOMERE LENGTH FOR 
CONTROL AND PMAD. THE Y AXIS IS THE VC AND THE X IS SARCOMERE LENGTH. BASELINE 
(FILLED) AND STRETCHED (OPEN) FOR PAIRS OF SIMILAR STRETCHES FROM ~1.8 µM ~ 2.0 
µM. VC WERE SIGNIFICANTLY LOWER IN PMAD (RED) THAN CONTROL (BLACK); MORE 
NEGATIVE IS FASTER RATE OF CONTRACTION . HOWEVER, THE PERCENTAGE CHANGE 
BETWEEN THE STRETCH AND BASELINE IN EACH GROUP WAS IDENTICAL (~152% OF 
BASELINE), N= 8, 9 CELLS FROM 3 AND 4 HEARTS FOR PMAD AND CONTROL HEARTS 
RESPECTIVELY. F. POOLED DATA COMPARING UNLOADED %SL VS ∆F/FPEAK OF CICR 
UNDER CONTROL, PMAD, EPINEPHRINE INFUSION IN ANIMAL, BUT NOT CELLS (EPI INF), AND 
EPINEPHRINE IN ISOLATED CELLS (EPI CELL), BUT NOT IN WHOLE ANIMAL), AS WELL AS 
PMAD IN PRESENCE OF ALDA-1 (PMAD-ALDA, N=25 CELLS FROM 4 ANIMALS). N FOR 
CONTROL, PMAD, AND EPI INF ARE THE SAME AS ABOVE. G. BASELINE FORCE (BSF) IN 
EXAMPLE CELLS PACED STEADILY AT 1 HZ IN CONTROL, PMAD, PMAD-KN, PMAD-RY 
CELLS. BSF WAS LOWER THAN CONTROL IN PMAD CELLS, BUT EVEN LOWER WHEN CALCIUM 
MEMORY WAS BLOCKED WITH EITHER RYANODINE OR KN93. H. POOLED DATA FOR BSF 
MEASUREMENTS AT 1 HZ STEADY-STATE PACING IN CONTROL, PMAD IN THE PRESENCE AND 
ABSENCE OF KN93 OR RYANODINE. N= 8, 8, 5, 4 CELLS FOR CONTROL, PMAD, PM AD-KN, 
PMAD-RY  
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FIGURE	3-9	-	HIGH VS LOW AFFINITY CALCIUM INDICATORS IN PMAD CALCIUM 
MEASUREMENTS.  
A. TWO SUPERIMPOSED CICR TRANSIENTS FROM THE SAME PMAD CELL POPULATION 
LOADED WITH EITHER WITH FLUO-5F (LOW AFFINITY, BLACK) OR WITH FLUO-4 (HIGH 
AFFINITY, RED) ARE SHOWN DEMONSTRATING THE SIGNIFICANT FILTERING EFFECT OF THE 
HIGHER AFFINITY DYE BOTH IN TERMS OF AMPLITUDE AND TIME COURSE. ON AVERAGE, 
DECAY PHASE WAS SIGNIFICANTLY PROLONGED TO 533 ± 16 MS WITH FLUO-4 (DATA NOT 
SHOWN), ~100 MS LONGER THAN FLUO-5F ( SEE TEXT). B. CALCIUM TRANSIENT ∆F/FPEAK 
FOR BOTH CONTROL (C) AND PMAD (P) CELLS MEASURED USING EITHER THE HIGH AFFINITY 
WAS HIGHER THAN THAT OBSERVED FOR LOW AFFINITY (LOW) OR HIGH AFFINITY (HIGH) FLUO 
DERIVATIVE. THE DIFFERENCE BETWEEN CONTROL AND PMAD WAS SUBSTANTIALLY MISSED 
USING THE HIGH AFFINITY DYE (ONLY ~152% FOR PMAD VS CONTROL ∆F/FPEAK, P=0.02, 
N=32 FROM 2 RATS FOR HIGH AFFINITY PMAD AND CONTROL).  IN ADDITION, THIS CLIPPING 
OF THE DATA CAN AT THE EXPENSE OF PROLONGED BUFFERING WITH HIGHER ∆F/FPEAK 
WITH HIGH AFFINITY DYE IN CONTROL AND FRANK SATURATION WITH LOWER ∆F/FPEAK WITH 
HIGH AFFINITY DYE IN PMAD COMPARED TO RESPECTIVE MEASUREMENTS WITH LOW 
AFFINITY DYE. C. THE RESTING DIASTOLIC LENGTH MEASURED JUST PRIOR TO THE NEXT 
STIMULUS IN A PACING TRAIN (Y AXIS) IS PLOTTED AGAINST PACING FREQUENCY (X-AXIS) IN 
CELLS LOAD WITHOUT DYE (GREEN), WITH LOW AFFINITY DYE (BLACK) OR HIGH AFFINITY DYE 
(RED) IN CONTROL (OPEN) AND PMAD CELLS (FILLED). AS CAN BE SEEN, HIGH AFFINITY DYE 
SIGNIFICANTLY PREVENTS THE CELL FROM RETURNING TO RESTING LENGTH AT ALL 
FREQUENCIES TESTED, A PROCESS THAT RESULTS FROM THE DOMINANT BUFFERING 
FEATURE OF THE DYE. C. %SL IN UNLOADED CELLS FROM CONTROL AND PMAD CELLS 
LOADED WITH HIGH OR LOW AFFINITY CALCIUM DYE AT STEADY-STATE1 HZ PACING. THE 
HIGH AFFINITY DYE REDUCES THE %SL IN CONTROL CELLS ALMOST AS MUCH AS CARDIAC 
DEATH DOES ALONE, WHILE THE LOW AFFINITY DYE AND 1 HZ PACING DOES NOT 
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APPRECIABLE ALTER CONTRACTILE PERFORMANCE. FOR ALL EXPERIMENTS ABOVE, N=32 
FROM 2 RATS FOR HIGH AFFINITY EXPERIMENTS IN BOTH PMAD AND CONTROL.  
 
 
3.8. Calcium Force Relationship 
As mentioned above, previous reports have documented an impaired 
myofilament affinity to calcium and a rightward shift in the force-pCa curve. 
However, many of these experiments relied on permeabilised preparations.70 
To overcome this limitation, other groups have investigated force-calcium 
relationships using whole muscle preparations and calcium concentration 
curves generated by varying extracellular calcium up to 30 mM in the 
presence of high affinity calcium dyes.70 For these reasons, we developed a 
technique to measure calcium fluorescence in dynamically contracting cells 
using the lower affinity calcium dye Fluo-5f to investigate the calcium-force 
relationship. 
The introduction of Fluo-5f did not distort the %SL (Figure 3.9). We explored 
the effects of load and CICR simultaneously in dynamically twitching fibers. 
It has been reported that CICR changes with stretch in amphibian cells,71 but 
this has not yet been reported in mammalian cells, so we first examined 
whether the CICR waveform is affected by load. We saw no appreciable 
differences in CICR with stretch (Figure 3.8 D). We next investigated length 
dependent activation, the putative mechanism for the Frank-Starling effect,72 
by comparing contraction velocity before and after stretch. We compared the 
changes in the velocity of contraction between a group of control and PMAD 
cells (Figure 3.8 E). In these cells, care was taken to equalise baseline and 
stretched sarcomere lengths. While the post-stretch change in velocity was 
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similar (ratio post to pre-stretch vc: 1.7±0.2 vs 1.8±0.2 for control vs PMAD, 
p=0.5), PMAD cells showed a significantly (36%) reduced length-dependent 
activation based on a decreased baseline velocity of contraction.  
We generated calcium-force-frequency-relationships (CFFR) for control and 
PMAD cells shown in Figure 3.10 A and 3.10 B. These plots summarize the 
reduced myofilament calcium sensitivity demonstrating a reduction in force 
across all frequencies despite a markedly elevated CICR. 
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FIGURE 3-10 – CALCIUM FORCE FREQUENCY RELATIONSHIPS AFTER CARDIAC 
ARREST 
A. PLOT OF FORCE, PACING FREQUENCY AND CALCIUM EXPRESSED AS ∆F/FPEAK FOR 
CONTROL CELLS AT SLACK LENGTH LOADED WITH FLUO-5F AND SIMULTANEOUSLY 
STRETCHED WITH CF. N=4 CELLS FROM 2 CONTROL HEARTS. THE CURVE SHOWS A STEEP 
CURVE SHIFTED TO LOWER ∆F/FPEAK. FORCE IS COLOR CODED WITH THE SAME PALLETTE 
AS IN PANEL B. B. SIMILAR PLOT IN POST ARREST CELLS. N=4 CELLS FROM 2 CONTROL 
HEARTS. BY COMPARISON TO PANEL A, THE CURVE IS SHIFTED TO A FLATTER CURVE 
DESPITE ALSO BEING SHIFTED TO HIGHER ∆F/FPEAKS (RIGHTWARD) AT ALL PACING 
FREQUENCIES. FORCE IS COLOR CODED WITH THE SAME PALLETTE AS IN PANEL A, AND ALL 
SCALE BARS ARE IDENTICAL. 
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3.9. CAMKII autophosphorylation increases post-cardiac 
arrest 
CAMKII is known to be a mediator of early long term potentiation in neurons. 
LTP is part of the spectrum of synaptic plasticity and is associated with 
enhanced signalling in which CAMKII autophosphorylation plays an 
important role. We hypothesized that CAMKII autophosphorylation was a 
critical mediator of calcium cardiac memory. To confirm this observation, we 
used immunoblot analysis of whole heart isolates flash frozen immediately 
after resuscitation in PMAD and compared this with control hearts similarly 
treated. Blots were analyzed with site-specific antibodies against total 
CAMKII (Figure 3.11, top panel), threonine-287 (T287; autophosphorylation 
site, middle panel), and beta-actin expression in control and PMAD.  CAMKII 
total expression increased non-significantly in PMAD compared with control 
hearts. However, the T287 autophosphorylation was significantly higher in 
PMAD.  
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FIGURE	3-11	–  CAMK PHOSPHORYLATION IN PMAD WITH AND WITHOUT ALDA-1. A. 
IMMUNOBLOTS AGAINST CAMKII (TOP PANEL), AUTOPHOSPHORYLATED (T287) CAMKII 
(MIDDLE PANEL), AND Β-ACTIN (BOTTOM PANEL) IN CONTROL (C), PMAD IN THE ABSENCE 
(P) AND PRESENCE OF ALDA-1 (A). B. QUANTITATIVE ASSESSMENT OF IMMUNE BLOT 
ANALYSIS AGAINST CAMKII NORMALIZED TO Β-ACTIN C. QUANTITATIVE ASSESSMENT OF 
IMMUNE BLOT ANALYSIS AGAINST AUTOPHOSPHORYLATED CAMKII NORMALIZED TO Β-
ACTIN. FOR AUTOPHOSPHORYLATED CAMKI, STUDENT T-TEST P=0.02291, AND MANN-
WHITNEY P=0.03 
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3.9.1. Alda-1 improves cardiac performance while 
reducing CICR in DCD 
 
Although much is known regarding the role of oxidative stress in ischemia 
and reperfusion, less is understood regarding aldehydic stress. Recently, it 
has been shown in the setting of myocardial infarction that ALDH2 plays a 
pivotal role in cardioprotective signalling and reduces ischemic damage 
through detoxification of reactive aldehydes (such as 4-HNE and 
acetaldehyde) to non-reactive acids (such as 4-hydroxynon-2-enoic acid and 
acetic acid). A small molecule activator of ALDH2 (Alda-1) prevents 
inhibition of ALDH2 (by 4-HNE) and, thus, ensures continued detoxification 
of reactive aldehydes during ischemia-reperfusion.73 We hypothesized that 
activating ALDH2 during in vivo cardiac arrest would improve myocardial 
performance. Indeed, Alda-1 administration had a dramatic positive impact. 
First, weaning from resuscitation in vivo (defined as reaching 20% of the pre-
arrest MAP) occurred in 63% (n=8 animals) of animals exposed to Alda-1 
compared with only 12% (n=30 animals) in the absence of Alda-1 after 
cardiac arrest (figure 3.12 D). Furthermore, the performance of the hearts 
weaned off bypass support after cardiac arrest was improved dramatically in 
the presence of Alda-1. In particular, we found that whole animal cardiac 
contractility, as indexed by ESPVR, PRSW, CI, and τ were returned to near 
control levels after Alda-1 (Table 3.2 and figure 3.12 A-C). At the cellular 
level, we found that that the increased CICR seen in PMAD was reduced by 
30% (Figure 3.8 B), and that the %SL vs CICR was improved as well to a 
state between control and PMAD (Figure 3.8 F). In addition, immunoblot 
analysis of CAMK and autophosphorylated CAMKII revealed that in the 
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presence of Alda-1 during cardiac arrest, T287 autophosphorylation was 
abrogated (Figure 3.11 B-C). Alda-1 had no effect on these same 
parameters before arrest 
 
 
Table 3.2 – In Vivo measurements  
  Control PMAD (P Value) Alda - PMAD 
ESPVR (mmHg/µl) 1.0±0.10 0.5±0.1 (0.02) 1.1±0.2 
PRSW (mmHg) 58±8 30±6 (0.02) 55±16 
CI (mmHg/µl)*s 93±6 64±6 (0.005) 89±12 
τ (ms) 12±3 45±6 (7e-11) 19±7 
TABLE 3. 2 - IN VIVO PARAMETERS; ESPVR, PRSW, CI AND TAU IN CONTROL 
N=11, PMAD N=30 AND PMAD WITH ALDA ON BOARD N=8. 
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FIGURE	3-12	– ALDA-1 IMPROVED IN VIVO CONTRACTILITY AND RECOVERY RATE TO 
SPONTANEOUS CIRCULATION AFTER CARDIAC ARREST. A, SUMMARY DATA FOR PRELOAD 
RECRUITABLE STROKE WORK (PRSW) FOR CONTROL, PMAD, AND PMAD-ALDA 
(P=0.04). B, SUMMARY DATA FOR CARDIAC INPUT (CI) FOR CONTROL, PMAD, AND PMAD-
ALDA. C, SUMMARY DATA FOR TAU FOR CONTROL, PMAD, AND PMAD-ALDA. D, ALDA-1 
IMPROVED CHANCES OF WEANING FROM ECMO RESUSCITATION. CONTROL N=11, PMAD 
=30 & PMAD-ALDA N=8. P VALUES IN GRAPHS ARE WITH RESPECT TO CONTROL USING 
POST HOC ANALYSIS. COMPARISONS BETWEEN GROUPS WERE PERFORMED WITH KRUSKALL-
WALLIS NONPARAMETRIC TESTS 
 
3.10. In Situ Optical Mapping of Voltage and Calcium in 
the Heart  
We chose di-4-ANBDQPQ53 to report Vm, and rhod-2(AM) to report [Ca2+]I
 
changes, as both dyes had previously been used successfully in diluted-
blood perfused Langendorff hearts.74 To avoid cross-talk between dye 
emissions, we made use of the ratiometric properties of di-4-ANBDQPQ.53,55  
As shown in Figure 3.13 A, excitation of this dye with either blue or red 
wavelengths produces action potential (AP) fluorescence signals that 
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increase or decrease with changes in Vm, respectively (although not used in 
this study, ratiometric Vm 
 
imaging can be used to reduce motion artifacts). 
During exposure to green light (used for excitation of rhod-2(AM)) there is no 
change in voltage- related emission, as this occurs at the excitation-
isosbestic point for di-4-ANBDQPQ. This approach allows simultaneous Vm
 
and [Ca2+]i
 
imaging (Figure 3.13) without emitted signal cross-talk.  
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FIGURE	3-13	-	SCHEMATIC ILLUSTRATION OF MULTI-PARAMETRIC IMAGING APPROACH. (A) DI-
4-ANBDQPQ FLUORESCENCE IN A LANGENDORFF-PERFUSED RAT HEART (SINUS RHYTHM), 
EXCITED WITH BLUE (BLUE LED, 470610 NM FILTER), GREEN (GREEN LED, 540612.5 NM 
FILTER) AND RED (RED LED, 640610 NM FILTER) WAVELENGTHS. THESE FLUORESCENCE 
SIGNALS (TAKEN FROM THE 464-PIXEL WHITE-SQUARE REGION ON THE LEFT-VENTRICLE) 
WERE COLLECTED THROUGH A CUSTOM-MADE MULTI-BAND EMISSION FILTER (F3 IN B, C). 
THE GREEN TRACE ([CA2+]I) SHOWS NEGLIGIBLE EMISSION CHANGES WHEN DI-4-
ANBDQPQ IS EXCITED AT THE EXCITATION- ISOSBESTIC POINT. SCALE BAR = 5 MM. (B) 
SCHEMATIC OUTLINE OF THE IMAGING SYSTEM, HIGHLIGHTING KEY COMPONENTS. SINCE 
ONLY ONE CAMERA IS USED, THE SYSTEM REQUIRES NO CHALLENGING OPTICAL ALIGNMENT. 
EXCITATION SOURCES EX1: RED LED WITH A 640610 NM FILTER (F1), EX2: GREEN LED 
WITH A 540612.5 NM FILTER (F2). (C) TRANSMISSION SPECTRUM OF THE CUSTOM MULTI-
BAND EMISSION FILTER THAT PASSES BOTH VM
 
(EM1) AND [CA2+]I
 
(EM2) EMITTED 
FLUORESCENCE SIGNALS. F1 AND F2 EXCITATION FILTER SPECTRA ARE SHOWN AS DASHED 
CURVES. (D) BASIC PRINCIPLE BEHIND THE SINGLE-CAMERA MULTI-LED APPROACH: DURING 
ANY FRAME EXPOSURE (OCCURRING BETWEEN THE VERTICAL DASHED LINES), THE 
PARAMETER BEING MEASURED BY THE CAMERA SENSOR IS DETERMINED BY THE EXCITATION 
SOURCE (EITHER EX1 OR EX2) THAT IS SWITCHED ON DURING THAT PERIOD. A SUFFICIENTLY 
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FAST CAMERA (COMPARED TO EM1 AND EM2 SIGNAL DYNAMICS), AND INTERPOLATION 
BETWEEN MEASURED DATA POINTS, PROVIDES SIMULTANEOUS MEASURES OF MULTIPLE 
PARAMETERS, HERE VM
 
AND [CA2+]I. FOR THESE IMAGES, BLEBBISTATIN WAS USED TO 
ELIMINATE THE CONTRIBUTION OF MOTION TO THE SIGNALS.	
 
 
 
 
A schematic illustration of the overall single-camera imaging/ multiple-LED 
excitation system is shown in Figure 3.13 B. The multi- band emission filter 
used (F3 in Figure 3.13 B) was custom-fabricated by Chroma Technology 
(Bellows Falls, VT, USA) to provide transmission bands for fluorescence 
emitted from both di-4- ANBDQPQ (Em1) and rhod-2(AM) (Em2; Figure 3.13 
C). Figure 3.13 D illustrates the principle behind our approach: During one 
camera frame-exposure, excitation light 1 (Ex1) is turned on, producing Vm
 
signal emission collected through the Em1-band; during the next frame 
exposure, excitation light source 2 (Ex2) is turned on, producing [Ca2+]i
 
signal emission collected through the Em2- band, and so on. Since the 
camera frame rate (here 500 frames- per-second; kHz frame rates can be 
achieved with pixel-binning) is faster than physiological signal dynamics, 
with interpolation, one can record electrophysiologically-relevant dynamic 
changes in both Vm
 
and [Ca2+]i
 
(such as the action potential [AP] and the 
calcium transient [CaT]), and assess AP and CaT propagation.  
 
 
Figure 3.14 shows results obtained using the imaging system in proof-of-
principle work on saline-perfused rat hearts in Langendorff mode. In Figure 
3.14 A, AP and CaT fluorescence signals from one location on the left 
ventricle are plotted, while Figure 3.14 B shows a time series of normalized 
Vm and [Ca2+]i fluorescence intensity maps, highlighting the well-known 
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delay (here about 17 ms) of the CaT peak relative to AP upstroke (see 
Movie M1 in eThesis). M1 shows AP and CaT fluorescence signals from four 
other points on the same heart, demonstrating signal quality across the 
whole field of view. Unless otherwise stated for these images and what 
follows, blebbistatin was used to reduce the contribution of motion to the 
fluorescence signals.  
 
 
FIGURE	3-14 - SIMULTANEOUS IMAGING OF VM
 
AND [CA2+]I
 
IN A LANGENDORFF-MODE SALINE-
PERFUSED RAT HEART. (A) VM
 
(RED) AND [CA2+]I
 
(GREEN) FLUORESCENCE SIGNALS 
(CAMERA SIGNALS ON A 16-BIT SCALE) TAKEN FROM THE 464-PIXEL WHITE-SQUARE REGION 
ON THE LEFT VENTRICLE. (B) NORMALIZED FLUORESCENCE INTENSITY MAPS (COLORBAR 
SHOWN) AT PROGRESSIVE TIME POINTS DURING SINUS RHYTHM. THE DELAY OF THE CAT 
RELATIVE TO THE AP PEAK (,17 MS FROM TRANSIENTS IN PART A) IS CLEARLY VISIBLE. 
SCALE BAR = 5 MM. FOR THESE IMAGES, BLEBBISTATIN WAS USED TO ELIMINATE THE 
CONTRIBUTION OF MOTION TO THE SIGNALS. 
 
 
 
Next, we applied our imaging system to the rat heart in vivo using di-4-
ANBDQPQ and rhod-2(AM) in isolation. Figure 3.15 shows the in vivo 
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preparation used (details can be found in the Methods section). In Figure 
3.15 F, we show summed results of the heart rate (in ms), PR, QRS, and 
QTc intervals for far field EKG recordings immediately before and 5 minutes 
after loading of voltage dye. We found no appreciable differences in these 
ECG traces (n = 3). In addition, mean arterial pressure (MAP) is shown 
again immediately before and 5 minutes after loading with voltage dye. 
There was no appreciable effect on MAP with voltage dye loading. As noted 
in the Methods section, to reduce motion contamination in both the Vm
 
and 
[Ca2+]i
 
fluorescence, blebbistatin was added during imaging. With the 
addition of blebbistatin we used cardiopulmonary bypass (CPB) circuit to 
maintain blood pressure as described in the Methods section.  
	
FIGURE	3-15	- IN VIVO RAT WHOLE-HEART PREPARATION. (A) A SCHEMATIC OF THE RAT 
CARDIOPULMONARY BYPASS (CPB) CIRCUIT BASED ON A STANDARD PUMP CIRCUIT (EJV: 
RIGHT EXTERNAL JUGULAR VEIN CATHETER, VR: VENOUS RESERVOIR, RP: ROLLER PUMP, 
MO: MINIATURE MEMBRANE OXYGENATOR, FA: RIGHT FEMORAL ARTERY CATHETER, AA: 
ASCENDING AORTA CATHETER VIA RIGHT CAROTID ARTERY). IN CPB MODE, BLOOD IS 
PUMPED FROM THE EJV THROUGH THE MO TO THE FA, EPICTED BY ARROWS IN THE FIGURE. 
DYE IS INJECTED THROUGH THE AA CATHETER. (B) WHOLE-ANIMAL VIEW OF THE 
PREPARATION. (C) ZOOMED-IN VIEW OF THE OPEN CHEST, WITH THE HEART IN CLEAR VIEW 
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(EL: ESOPHAGEAL ECG LEAD, ET: ENDOTRACHEAL TUBE). (D) AN EXAMPLE OF RVP AT 12 
HZ TO DROP BLOOD PRESSURE (BP; RED TRACE), AFTER WHICH DYE WAS INJECTED VIA THE 
AORTIC ROOT. THE BP RECOVERED SOON AFTER CESSATION OF PACING. IMMEDIATELY 
AFTER LOADING AS SHOWN HERE, THE BP INCREASED REFLECTING THE FRANK-STARLING 
EFFECT OF PROLONGED LOADING. THE ACCOMPANYING ECG (BLACK TRACE) IS ALSO 
SHOWN. (E) ZOOMED-IN VIEW OF THE HEART IMMEDIATELY AFTER RHOD-2(AM) INJECTION 
DEMONSTRATING A FLUORESCENT CORONARY ANGIOGRAM. (F) POOLED DATA ON HEART 
RATE (HR IN MS), MEAN ARTERIAL BP (MAP IN MMHG—RIGHT AXIS), AS WELL AS FAR FIELD 
EKG PARAMETERS OF PR, QRS, AND QTC INTERVALS (IN MS) FOR IMMEDIATELY BEFORE 
(BLACK) AND AT 5 MINUTES AFTER LOADING WITH VOLTAGE DYE (RED). 
 
 
 
 
 
Figure 3.16A shows normalized Vm
 
fluorescence intensity maps at 
progressive time points in a heart in vivo (see Movie M2 in eThesis). Figure 
3.16B shows normalized Vm
 
fluorescence intensity maps at progressive time 
points 1 hour after LAD suture ligation to induce local myocardial infarction 
(to be differentiated from scar) (see Movie M3 in eThesis). In the left panel, a 
raw grayscale fluorescence image of Vm
 
signal emission during diastole 
shows that the infarcted tissue is darker than surrounding normal 
myocardium (upper right quadrant), as the dye cannot reach the infarct. In 
the normalized Vm
 
fluorescence intensity maps, AP propagation proceeds 
through viable tissue (best appreciated in Movie M3 in eThesis). In Figure 
3.16C, we show a necropsy specimen of the endocardial surface of the 
same heart, highlighting Vm
 
emission differences at the normal (bright) and 
infarcted (dark) tissue. The left panel in Figure 3.16C shows the specimen 
submersed beneath 1 cm of blood, while on the right, a coverslip has been 
placed on the tissue (bubbles highlight the coverslip-tissue interface). This 
gross demonstration of normal versus infarct tissue illustrates the ability of 
the dye to differentiate between the two tissue types rapidly. Clearly, 
collateralization of infarcted tissue by remodelling, and identification of scar 
from viable tissue will be critical to investigate, as has been done using 
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voltage dyes in vitro.50 But, this was not possible in this small animal model 
because, while the LAD infarct did indeed lead to scar formation we did not 
see collateralization in our infarct model. In Figure 3.16D, we show an 
example of calcium fluorescence measurements in vivo. Here, normalized 
[Ca2+]i
 
fluorescence intensity maps are shown for the epicardial surface 
containing the atria. The activity shown is during atrial fibrillation. Because 
the electrical activation frequency of atrial fibrillation is exceedingly high (8–9 
Hz in the rat) and disorganised, atrial contraction is uncoordinated. While 
this is detrimental clinically, imaging is improved as movement is minimized 
(no blebbistatin needed; see Movie M4 in eThesis).  
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FIGURE	3-16 - IN VIVO IMAGING OF VM
 
AND [CA2+]I
 
DYNAMICS IN RAT VENTRICLES/ATRIUM, 
DURING SINUS RHYTHM AND IN ATRIAL FIBRILLATION. (A) NORMALIZED VM
 
FLUORESCENCE 
INTENSITY MAPS (COLOUR BAR SHOWN) AT PROGRESSIVE TIME POINTS OF THE CARDIAC 
CYCLE WITH THE HEART IN SINUS RHYTHM. (B) NORMALIZED VM
 
FLUORESCENCE INTENSITY 
MAPS AT SEQUENTIAL TIME POINTS OF THE HEART IN SINUS RHYTHM, 1 HOUR AFTER SUTURE-
LIGATION OF THE PROXIMAL LAD (TO MIMIC MYOCARDIAL INFARCTION). IN THE LEFT-MOST 
(RAW GRAYSCALE) PANEL, THE INFARCTED TISSUE CAN BE RECOGNIZED AS THE DARK 
REGION (ONE SIDE DEMARCATED BY DOTTED WHITE LINE) IN THE TOP-RIGHT QUADRANT OF 
THE IMAGE; IN THE NORMALIZED FLUORESCENCE MAPS IT IS RECOGNIZED AS THE 
PERSISTENTLY BLUE REGION IN THE SAME AREA. SUTURE LOCATION IS INDICATED WITH A 
WHITE ARROW. THE ASTERISK MARKS LUNG TISSUE. (C) ENDOCARDIAL VIEW OF SAME 
INFRACTED HEART AS IN (B), AFTER NECROPSY, SUBMERGED IN BLOOD (LEFT) AND WITH A 
COVERSLIP GENTLY PLACED ON THE TISSUE (RIGHT). THE BRIGHT AREAS CORRESPOND TO 
NON-INFARCTED TISSUE, WHILE THE DARK AREAS CORRESPOND TO INFARCTED TISSUE 
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WHERE THE DYE IS ABSENT. THE DASHED WHITE LINE DEMARCATES HEART TISSUE BORDER. 
NOTE THE AIR BUBBLES ON THE LEFT SIDE OF THE PANEL AT THE COVERSLIP-TISSUE 
INTERFACE. (D) NORMALIZED [CA2+]I
 
FLUORESCENCE INTENSITY MAPS AT SEQUENTIAL 
CAMERA FRAMES IN PART OF THE LEFT AND RIGHT ATRIA DURING ATRIAL FIBRILLATION, 
INDUCED BY GLOBAL VENTILATORY HYPOXIA. SCALE BAR = 5 MM. FOR A AND B, 
BLEBBISTATIN WAS USED TO REDUCE, BUT NOT ELIMINATE, THE CONTRIBUTION OF MOTION 
TO THE SIGNALS, WHILE FOR C, NO BLEBBISTATIN WAS USED. TISSUE SHOWN IN B AND C 
CORRESPOND TO A DIFFERENT HEART THAN THAT SHOWN IN A.	
 
 
 
In the final set of experiments, we dual-loaded the in vivo heart with both 
rhod-2(AM) and di-4-ANBDQPQ. Figure 3.17A shows Vm
 
(red) and [Ca2+]i
 
(green) fluorescence signals from a point on the left ventricle, demonstrating 
AP and CaT measurements (some motion artefacts present in signals). 
Figure 3.17B shows normalized Vm
 
and [Ca2+]i
 
fluorescence intensity maps 
at progressive time points from the same heart (see Movie M5 in eThesis). 
Figure 3.17C shows Vm
 
(top traces) and [Ca2+]i
 
(bottom traces) 
fluorescence signals from three points on the left ventricle of another heart, 
demonstrating varying motion artefact effects when contraction is not 
completely eliminated. In contrast to the loading of di-4-ANBDQPQ, during 
which hemodynamic effects were not seen, rhod-2(AM) application by direct 
root injection required ECMO support, as the [Ca2+]i
 
dye could lead to 
asystolic arrest during initial injection, with subsequent beating recoverable 
with circulatory support (which was always needed for calcium dye 
experiments). Dye loading protocols in vivo need to be optimised. Our data, 
however, shows that it is possible in principal to conduct combined Vm
 
and 
[Ca2+]i
 
imaging in the blood-perfused mammalian heart in vivo.  
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FIGURE	3-17	-	IN	VIVO	IMAGING	OF	VM
	
AND	[CA2+]I
	
DYNAMICS	IN	RAT	VENTRICLES	DURING	SINUS	
RHYTHM.	(A)	AP	(RED)	AND	CAT	(GREEN)	FLUORESCENCE	SIGNALS	TAKEN	FROM	THE	464-PIXEL	
WHITE-SQUARE	REGION	HIGHLIGHTED	IN	THE	TOP	PANEL	(LEFT	VENTRICLE).	(B)	NORMALIZED	
FLUORESCENCE	INTENSITY	MAPS	(COLORBAR	SHOWN)	FOR	VM
	
AND	[CA2+]I
	
DURING	SINUS	RHYTHM	
FROM	THE	SAME	HEART;	NOTE	THE	PREVIOUSLY	MENTIONED	DELAY	BETWEEN	VM
	
AND	[CA2+]I
	
PEAKS	(RED	ARROW	INDICATES	ELECTRICAL	WAVE	PROPAGATION	DIRECTION).	(C)	AP	(TOP	TRACES)	
AND	CAT	(BOTTOM	TRACES)	FLUORESCENCE	SIGNALS	TAKEN	FROM	THREE	464-PIXEL	SQUARE	
REGIONS	FROM	THE	LEFT	VENTRICLE	OF	ANOTHER	HEART,	SHOWING	VARYING	MOTION	ARTIFACT	
EFFECTS.	SCALE	BAR	=	5	MM.	FOR	THESE	IMAGES,	BLEBBISTATIN	WAS	USED	TO	REDUCE,	BUT	NOT	
ELIMINATE,	THE	CONTRIBUTION	OF	MOTION	TO	THE	SIGNALS.	FOR	B,	NON-UNIFORM	DYE-LOADING	
AND	MOTION	ARTIFACT	ARE	THE	CAUSE	OF	SIGNAL	QUALITY	HETEROGENEITY.	
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CHAPTER 4. DISCUSSION AND CONCLUSIONS 
 
It has been recognized for more than three decades that following cardiac 
arrest, myocardial dysfunction occurs32 and is a critical factor in recovery.31 
To date, most research focused on ischemia-reperfusion has used a 
Langendorff isolated heart preparation to investigate mechanisms and 
concluded that calcium transients are not increased. Here, we have 
developed an in vivo model of post-myocardial cardiac arrest ventricular 
dysfunction which leaves neurohormonal responses intact. Using this model, 
we describe a greatly increased calcium induced calcium release in isolated 
cardiac myocytes reproduced by in vivo epinephrine infusion and brain stem 
death. We also find cardiac calcium memory to be mediated by 
autophosphorylation of CAMKII. We also find it to be dependent on 
ryanodine receptor calcium but not PKA activation in vivo. Finally, we found 
that a small molecular activator of the aldehyde dehydrogenase 2 
dramatically improves cardiac performance at the whole heart and cellular 
level and reduces autophosphorylation of CAMKII, consistent with a role for 
aldehydic stress in the injury mechanism.  
The role of CAMKII has been described in seminal investigations.42,75-77 Its 
activation has been found to be important in the generation of electrical 
storm73 while after I/R, inhibition can prevent the occurrence of ventricular 
arrhythmias.78 Here we hypothesize that acute myofilament dysfunction 
leads to an increase in CICR which leads to auto-activation of CAMKII and 
triggers a more prolonged negative remodelling that can lead to 
cardiomyopathy. Such a proposed mechanism has similarities to neuronal 
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plasticity where CAMKII senses phasic changes and augments post-
synaptic signals.79 We speculate that just as the brain induces long-term 
potentiation80 in the heart, the unique features of CAMKII 
autophosphorylation and its ability to follow calcium changes phasically77 
allow integration of the “post-synaptic” dyadic cleft calcium and generate a 
series of myopathic changes.42,68,81-84 
 
In addition, we describe a system for measuring force and calcium 
simultaneously in isolated myocytes and establish a role for length 
dependent activation in the single cell Frank-Starling effect. Cell shortening, 
while a reliable measure as an indicator of cell function grossly, does not 
allow interrogation of the cellular equivalent of the Frank-Starling Law. 
Furthermore, in spite of the important information gleaned from the carbon 
fiber system on load-dependent force, the underlying mechanism of calcium 
regulated length dependent activation cannot be fully characterised without 
some characterisation of calcium and force. Indeed, while surrogates of the 
role of calcium on isometric force can be made with skinned fiber 
preparations, one of the critical components missing in understanding force 
generation is a description of the dynamic calcium-force interaction in 
response to action potential evoked CICR.85  
 
Our data has several limitations. We cannot directly verify whether 
adrenergic activation persists in the isolated cells. It is worth noting that the 
response to acute catecholamines, however, was different than subacute 
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infusion, and that calcium cardiac memory was CAMKII dependent, not PKA 
dependent. Furthermore, existing data in cultured ventricular cells has 
already demonstrated that catecholaminergic signalling switches from a PKA 
dependent pathway to a CAMKII dependent pathway with more chronic 
infusion. Though we have demonstrated that calcium measurements can be 
made in live animals in situ, the complexity of cardiac arrest with recovery 
and calcium dye measurements has at present been elusive. Preliminary 
data from brainstem herniation seems to support the in vivo expression of 
calcium cardiac memory, though this remains to be verified as the technique 
of in vivo measurements is perfected.  
 
We show that inhibiting aldehydic adduct formation during arrest/reperfusion 
increases myofilament sensitivity, reduces CaMKII activation, and improves 
survival. These mechanisms should be explored further as potential targets 
for human therapeutic trials.  
 
With in-situ Optical Mapping of Voltage and Calcium in the heart we 
introduce a multi-parametric imaging approach, building on a near-infrared 
voltage dye and red-shifted calcium dye, which relies on a multi-band filter to 
study two key parameters responsible for arrhythmia in vivo using a single 
camera. The technique, also suitable for Langendorff-perfused hearts, is 
scalable and less expensive than traditional optical mapping methods. In 
contrast to the single previous report on in vivo optical mapping,51 our 
system is adaptable, in principle, to trans-catheter endoscopic methods, 
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such as used to visualise the endocardium in humans86-89 opening the door 
to clinical development as an arrhythmia mapping tool.  
 
Because EAM suffers from suboptimal spatiotemporal resolution and can be 
very time consuming,90,91 alternative invasive modalities have been 
developed to circumvent some of these limitations. As an example, direct 
endocardial visualisation through optical catheters can simplify the 
procedure of ablation by relying on visualized anatomy through a saline-filled 
balloon.92,93  However, visualization catheters do not report complex 
electrical activity by comparison to EAM. With its high spatiotemporal 
resolution, optical mapping may meet this need by allowing for complex 
electrophysiology and direct anatomy to be mapped simultaneously through 
a minimally invasive approach. In addition, because optical catheters can 
visualize ablation lesions,87 in combination with optical mapping, it may be 
possible to visualize the interplay of ablation lesions and electrical block. 
Optical mapping also allows [Ca2+]i
 
measurements, a parameter not 
accessible to traditional EAM. Given the interplay of Vm
 
and [Ca2+]i
 
in 
arrhythmogenesis,49 clinically mapping this parameter could be fruitful. 
Finally, optical mapping can be conducted beat by beat, allowing for 
mapping of transient arrhythmias or infrequent ectopic events.  
 
In-situ optical mapping has several limitations. First and foremost, we have 
yet to couple our imaging system to a direct visualisation catheter. Second, 
in our experiments, excitation-contraction un-couplers were needed to 
reduce motion artifact from fluorescence transients, which is undesirable. 
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However, motion correction algorithms94 and ratiometric imaging of 
fluorescence transients95 have been used extensively to deal with motion 
artifacts in signals. In the isolated heart preparation, mechanical restriction 
or ratiometric imaging with post-acquisition motion tracking has been shown 
to significantly reduce motion artifacts, but imaging a strongly contracting 
whole-heart is still an unsolved problem.52 Indeed, an even simpler approach 
has been used with direct visualisation catheters where local mechanical 
immobilisation by the endocardial balloon successfully limits motion 
artifacts,86 even as applied to high resolution laser based ablation in 
patients.96 Third, while we found no evidence of short-term detrimental 
effects of di-4-ANBDQPQ, long term toxicity studies need to be done. 
However, the recent track record in voltage-sensitive dye development has 
been impressive, making us optimistic overall. Fourth, the calcium arrest 
seen during in vivo loading is thought to be caused by the calcium-buffering 
properties of the dye on either intra- or extracellular calcium levels. Further 
exploration of lower- affinity calcium dyes with red-shifted emissions may 
prove fruitful. In spite of these significant limitations discussed above, this 
proof-of-principle investigation confirms that ‘optical EAM’ is possible in vivo 
and argues for continued development.  
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CHAPTER 5. FUTURE DIRECTION 
 
Our aim was to undertake scientific assessment of hearts resuscitated 
following circulatory arrest using a small animal model of DCD heart 
donation. We hypothesized that reperfusion of the heart after cardiac arrest 
would result in recovery of cardiac activity with sufficient function to allow for 
transplantation. The hypothesis was based on the fact that historical 
experience of heart transplantation used organs removed after cardiac 
arrest.  
 
Having shown that following cardiac arrest with a 15 minute warm ischaemic 
time it is possible to resuscitate the heart and also by treating the animals 
with a small molecular activator of the aldehyde dehydrogenase 2 to 
dramatically improve the cardiac function at the whole heart and cellular 
level opens doors to the potential of using hearts from the DCD donor for 
transplantation. We show that inhibiting aldehydic adduct formation during 
arrest/reperfusion increases myofilament sensitivity, reduces CaMKII 
activation, and improves survival. These mechanisms should be explored 
further as potential targets for human therapeutic trials.  
 
Work from our group has carried on looking into DCD hearts as potential 
organs for transplantation – in particular with regards to resuscitation in the 
donor and then ex-vivo blood perfusion on a custom rig. The organ care 
system developed by Transmedics is an example of an ex-vivo perfusion 
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system designed to perfuse the donor heart with oxygenated blood. This 
device allows for continuous biochemical assessment as well as functional 
assessment. 
 
In July 2014 the first adult heart transplant from a DCD donor was 
transplanted in Australia.97  In March of 2015 Papworth Hospital performed 
the first DCD heart transplant in Europe. The clinical programme is ongoing 
and so far 32 DCD hearts have been transplanted successfully. Early 
combined international results from 4 centres utilising DCD donor hearts 
have reported a 30 day survival of 96.4%.98 At Papworth hospital DCD 
donors have increased the overall cardiac transplant activity by 45%.99  
These short-term results have been reassuring and we await long term 
follow up.  
 
Further work is currently ongoing into reconditioning of both the DCD and 
DBD hearts with ex-vivo perfusion. The agonal phase in the DCD donor can 
vary greatly from 1 minute – 130 minutes,99 the impact of this on donor heart 
function is unknown and this provides an avenue for future research.  
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CHAPTER 6. APPENDICES 
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The work described in this thesis was conducted between May 2010 to 
October 2011, at the Falk Cardiovascular Research Institute at Stanford 
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6.2. RESEARCH FUNDING  	
The author was awarded The Gledhill Fellowship by Papworth Hospital NHS 
Foundation Trust. The work at Stanford was supported by Dr. Euan Ashley’s 
laboratory.  
 
6.3. ATTRIBUTIONS  	
The author is very grateful to contributions to this body of research made by 
colleagues and collaborators.  I would like to thank Photometrics for 
graciously loaning their Evolve- 128 EMCCD camera for the in vivo studies.  
The author is directly responsible for the design, planning, execution and 
analyses of all experiments and the preparation of this thesis  
 
 
.  
	 93	
CHAPTER 7. BIBLIOGRAPHY 
 
 
1. Large, S. R. Is there a crisis in cardiac transplantation? Lancet 359, 
803–804 (2002). 
2. Alonso, A. et al. Renal Transplantation From Non–Heart-Beating 
Donors: A Single-Center 10-Year Experience. Transplant Proc 37, 
3658–3660 (2005). 
3. D'alessandro, A. M. et al. Liver transplantation from controlled non-
heart-beating donors. Surgery 128, 579–588 (2000). 
4. Abt, P. L. et al. Survival following liver transplantation from non-heart-
beating donors. Ann. Surg. 239, 87–92 (2004). 
5. De Vleeschauwer, S. et al. Early outcome after lung transplantation 
from non-heart-beating donors is comparable to heart-beating donors. 
J Heart Lung Transplant 28, 380–387 (2009). 
6. Steen, S. et al. Transplantation of lungs from non-heart-beating donors 
after functional assessment ex vivo. ATS 76, 244–52– discussion 252 
(2003). 
7. Barnard, C. N. The operation. A human cardiac transplant: an interim 
report of a successful operation performed at Groote Schuur Hospital, 
Cape Town. S. Afr. Med. J. 41, 1271–1274 (1967). 
8. Boucek, M. M. et al. Pediatric heart transplantation after declaration of 
cardiocirculatory death. N Engl J Med 359, 709–714 (2008). 
9. Ali, A. et al. Cardiac recovery in a human non-heart-beating donor 
after extracorporeal perfusion: source for human heart donation? J 
Heart Lung Transplant 28, 290–293 (2009). 
10. Noterdaeme, T. et al. What is the potential increase in the heart graft 
pool by cardiac donation after circulatory death? Transplant 
International 26, 61–66 (2012). 
11. Van Norman, G. A. Another Matter of Life and DeathWhat Every 
Anesthesiologist Should Know about the Ethical, Legal, and Policy 
Implications of the Non–Heart-beating Cadaver Organ Donor. 
Anesthesiology 98, 763–773 (2003). 
12. A definition of irreversible coma. Report of the Ad Hoc Committee of 
the Harvard Medical School to Examine the Definition of Brain Death. 
JAMA 205, 337–340 (1968). 
13. Vliet, V. D., Slooff, M. J. H., Rijkmans, B. G. & Kootstra, G. Use of 
Non-Heart-Beating Donor Kidneys for Transplantation. Eur Surg Res 
13, 354–360 (1981). 
14. MA, V., KM, L., GG, P. & G, K. Short- and long-term results with adult 
non-heart-beating donor kidneys. Transplant Proc 20, 743–745 (1988). 
15. Wynen, R. M. et al. Long-term follow-up of transplanted non-heart-
beating donor kidneys: preliminary results of a retrospective study. 
Transplant Proc 25, 1522–1523 (1993). 
16. Wijnen, R. M. et al. Outcome of transplantation of non-heart-beating 
donor kidneys. Lancet 345, 1067–1070 (1995). 
17. Matesanz, R. & Miranda, B. Outcome of transplantation of non-heart-
beating donor kidneys. Lancet 346, 53 (1995). 
	 94	
18. Daemen, J. H. et al. Non-heart-beating donor program contributes 
40% of kidneys for transplantation. Transplant Proc 28, 105–106 
(1996). 
19. TRANSPLANTATION, N. B. A. Organ Donationand Transplantation. 
1–167 (2015). 
20. Purshouse, K., Large, S., Dargie, H., Dunning, J. & Neuberger, J. Is 
There a Crisis in Heart Transplantation? Reflection over 10 Years. 
Open Journal of Organ Transplant Surgery 2, 1–4 (2012). 
21. TRANSPLANTATION, N. B. A. ANNUAL REPORT ON 
CARDIOTHORACIC TRANSPLANTATION 2014/15. 1–131 (2015). 
22. Lannon, J. D. et al. The UK Retrieval Team ‘Scout’ Pilot Programme. 
HEALUN 33, S162 (2014). 
23. McKeown, D. W., Bonser, R. S. & Kellum, J. A. Management of the 
heartbeating brain-dead organ donor. British Journal of Anaesthesia 
108, i96–i107 (2011). 
24. Salim, A. et al. The Effect of a Protocol of Aggressive Donor 
Management: Implications for the National Organ Donor Shortage. J 
Trauma 61, 429–435 (2006). 
25. Grafton, G., Samoukovic, G. & Colvin, M. M. Cardiac Donor Selection 
and Management. Curr Transpl Rep 2, 338–344 (2015). 
26. FOUNDATION, B. H. AHeart transplant will transformmy life. 1–41 
(2015). 
27. Nolan, J. P. et al. Post-cardiac arrest syndrome: Epidemiology, 
pathophysiology, treatment, and prognostication. Resuscitation 79, 
350–379 (2008). 
28. Stub, D., Bernard, S., Duffy, S. J. & Kaye, D. M. Post Cardiac Arrest 
Syndrome: A Review of Therapeutic Strategies. Circulation 123, 
1428–1435 (2011). 
29. Kilgannon, J. H. et al. Early arterial hypotension is common in the 
post-cardiac arrest syndrome and associated with increased in-
hospital mortality. Resuscitation 79, 410–416 (2008). 
30. Zia, A. & Kern, K. B. Management of postcardiac arrest myocardial 
dysfunction. Current Opinion in Critical Care 17, 241–246 (2011). 
31. Kern, K. B., Hilwig, R. W., Rhee, K. H. & Berg, R. A. Myocardial 
dysfunction after resuscitation from cardiac arrest: an example of 
global myocardial stunning. J Am Coll Cardiol 28, 232–240 (1996). 
32. Bolli, R. & Marbán, E. Molecular and cellular mechanisms of 
myocardial stunning. Physiological Reviews 79, 609–634 (1999). 
33. Zaugg, C. E., Ziegler, A., LEE, R. J., Barbosa, V. & Buser, P. T. 
Postresuscitation stunning: postfibrillatory myocardial dysfunction 
caused by reduced myofilament Ca2+ responsiveness after ventricular 
fibrillation-induced myocyte Ca2+ overload. Journal of Cardiovascular 
Electrophysiology 13, 1017–1024 (2002). 
34. Weiss, J. N., Nivala, M., Garfinkel, A. & Qu, Z. Alternans and 
Arrhythmias: From Cell to Heart. Circulation Research 108, 98–112 
(2011). 
35. Kim, S.-J., Depre, C. & Vatner, S. F. Novel mechanisms mediating 
stunned myocardium. Heart Fail Rev 8, 143–153 (2003). 
36. Solaro, R. J. & Arteaga, G. M. Heart failure, ischemia/reperfusion 
injury and cardiac troponin. Adv. Exp. Med. Biol. 592, 191–200 (2007). 
	 95	
37. Salas, M. A. et al. Journal of Molecular and Cellular Cardiology. 
Journal of Molecular and Cellular Cardiology 48, 1298–1306 (2010). 
38. Vittone, L., Mundiña-Weilenmann, C. & Mattiazzi, A. Phospholamban 
phosphorylation by CaMKII under pathophysiological conditions. Front. 
Biosci. 13, 5988–6005 (2008). 
39. VALVERDE, C. et al. Phospholamban phosphorylation sites enhance 
the recovery of intracellular Ca2+ after perfusion arrest in isolated, 
perfused mouse heart. Cardiovascular Research 70, 335–345 (2006). 
40. Valverde, C. A. et al. Transient Ca2+ depletion of the sarcoplasmic 
reticulum at the onset of reperfusion. Cardiovascular Research 85, 
671–680 (2010). 
41. Kusuoka, H., Koretsune, Y., Chacko, V. P., Weisfeldt, M. L. & Marbán, 
E. Excitation-contraction coupling in postischemic myocardium. Does 
failure of activator Ca2+ transients underlie stunning? Circulation 
Research 66, 1268–1276 (1990). 
42. Zhang, R. et al. Calmodulin kinase II inhibition protects against 
structural heart disease. Nat Med 11, 409–417 (2005). 
43. Ali, A. A. et al. Hearts From DCD Donors Display Acceptable 
Biventricular Function After Heart Transplantation in Pigs. American 
Journal of Transplantation 11, 1621–1632 (2011). 
44. Bhakta, D. & Miller, J. M. Principles of electroanatomic mapping. 
Indian Pacing Electrophysiol J 8, 32–50 (2008). 
45. Gepstein, L., Hayam, G. & Ben-Haim, S. A. A novel method for 
nonfluoroscopic catheter-based electroanatomical mapping of the 
heart. In vitro and in vivo accuracy results. Circulation 95, 1611–1622 
(1997). 
46. Efimov, I. R. Optical Imaging of the Heart. Circulation Research 95, 
21–33 (2004). 
47. Salama, G. & Hwang, S.-M. Simultaneous optical mapping of 
intracellular free calcium and action potentials from Langendorff 
perfused hearts. Curr Protoc Cytom Chapter 12, Unit 12.17 (2009). 
48. Skrzypiec-Spring, M., Grotthus, B., Szelag, A. & Schulz, R. Isolated 
heart perfusion according to Langendorff---still viable in the new 
millennium. J Pharmacol Toxicol Methods 55, 113–126 (2007). 
49. Bers, D. M. Calcium Cycling and Signaling in Cardiac Myocytes. Annu. 
Rev. Physiol. 70, 23–49 (2008). 
50. DING, C. et al. High-Resolution Optical Mapping of Ventricular 
Tachycardia in Rats with Chronic Myocardial Infarction. Pacing and 
Clinical Electrophysiology 33, 687–695 (2010). 
51. Dillon, S. M., Kerner, T. E. & Hoffman, J. A system for in-vivo cardiac 
optical mapping. IEEE Eng Med Biol Mag 95–108 (1998). 
52. Herron, T. J., Lee, P. & Jalife, J. Optical Imaging of Voltage and 
Calcium in Cardiac Cells & Tissues. Circulation Research 110, 609–
623 (2012). 
53. Matiukas, A. et al. Near-infrared voltage-sensitive fluorescent dyes 
optimized for optical mapping in blood-perfused myocardium. HRTHM 
4, 1441–1451 (2007). 
54. Waggoner, A. S., Wachman, E. S. & Farkas, D. L. Optical filtering 
systems for wavelength selection in light microscopy. Curr Protoc 
Cytom Chapter 2, Unit 2.4 (2001). 
	 96	
55. Lee, P. et al. Single-sensor system for spatially resolved, continuous, 
and multiparametric optical mapping of cardiac tissue. Heart Rhythm 
8, 1482–1491 (2011). 
56. Entcheva, E., Kostov, Y., Tchernev, E. & Tung, L. Fluorescence 
imaging of electrical activity in cardiac cells using an all-solid-state 
system. IEEE Trans Biomed Eng 51, 333–341 (2004). 
57. van der Hoeven, J. A. et al. Induction of organ dysfunction and up-
regulation of inflammatory markers in the liver and kidneys of 
hypotensive brain dead rats: a model to study marginal organ donors. 
Transplantation 68, 1884–1890 (1999). 
58. Charo, D. N. et al. Endogenous regulation of cardiovascular function 
by apelin-APJ. Am J Physiol Heart Circ Physiol 297, H1904–13 
(2009). 
59. Woods, C. E., Novo, D., DiFranco, M. & Vergara, J. L. The action 
potential-evoked sarcoplasmic reticulum calcium release is impaired in 
mdx mouse muscle fibres. J. Physiol. (Lond.) 557, 59–75 (2004). 
60. Iribe, G., Helmes, M. & Kohl, P. Force-length relations in isolated intact 
cardiomyocytes subjected to dynamic changes in mechanical load. Am 
J Physiol Heart Circ Physiol 292, H1487–H1497 (2006). 
61. Bollensdorff, C., Lookin, O. & Kohl, P. Assessment of contractility in 
intact ventricular cardiomyocytes using the dimensionless ‘Frank–
Starling Gain’ index. Pflugers Arch - Eur J Physiol 462, 39–48 (2011). 
62. Cribier, A. et al. Technique of transcatheter aortic valve implantation 
with the Edwards-Sapien heart valve using the transfemoral approach. 
Herz 34, 347–356 (2009). 
63. Fedorov, V. V. et al. Application of blebbistatin as an excitation-
contraction uncoupler for electrophysiologic study of rat and rabbit 
hearts. HRTHM 4, 619–626 (2007). 
64. Edgar, P., Bullock, R. & Bonner, S. Management of the potential heart-
beating organ donor. Contin Educ Anaesth Crit Care Pain 4, 86–90 
(2004). 
65. Novitzky, D., Wicomb, W. N., Cooper, D. & Rose, A. G. Novitzky: 
Electrocardiographic, hemodynamic and endocrine... - Google 
Scholar. (J Heart Transplant, 1984). 
66. Szabó, G. et al. Role of neural and humoral factors in hyperdynamic 
reaction and cardiac dysfunction following brain death. HEALUN 19, 
683–693 (2000). 
67. Szabó, G., Hackert, T., Sebening, C., Vahl, C. F. & Hagl, S. 
Modulation of coronary perfusion pressure can reverse cardiac 
dysfunction after brain death. ATS 67, 18–25– discussion 25–6 (1999). 
68. Grimm, M. & Brown, J. H. β-Adrenergic receptor signaling in the heart: 
Role of CaMKII. Journal of Molecular and Cellular Cardiology 48, 322–
330 (2010). 
69. Wang, W. Sustained  1-Adrenergic Stimulation Modulates Cardiac 
Contractility by Ca2+/Calmodulin Kinase Signaling Pathway. 
Circulation Research 95, 798–806 (2004). 
70. Gao, W. D., Backx, P. H., Azan-Backx, M. & Marbán, E. Myofilament 
Ca2+ sensitivity in intact versus skinned rat ventricular muscle. 
Circulation Research 74, 408–415 (1994). 
71. Fabiato, A. & Fabiato, F. Dependence of the contractile activation of 
	 97	
skinned cardiac cells on the sarcomere length. Nature 256, 54–56 
(1975). 
72. de Tombe, P. P. et al. Journal of Molecular and Cellular Cardiology. 
Journal of Molecular and Cellular Cardiology 48, 851–858 (2010). 
73. Chen, C.-H. et al. Activation of aldehyde dehydrogenase-2 reduces 
ischemic damage to the heart. Science 321, 1493–1495 (2008). 
74. Qian, Y. W., Clusin, W. T., Lin, S. F., Han, J. & Sung, R. J. Spatial 
Heterogeneity of Calcium Transient Alternans During the Early Phase 
of Myocardial Ischemia in the Blood-Perfused Rabbit Heart. Circulation 
104, 2082–2087 (2001). 
75. Grueter, C. E., Colbran, R. J. & Anderson, M. E. CaMKII, an emerging 
molecular driver for calcium homeostasis, arrhythmias, and cardiac 
dysfunction. J Mol Med 85, 5–14 (2006). 
76. Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198–
205 (2002). 
77. Song, Q., Saucerman, J. J., Bossuyt, J. & Bers, D. M. Differential 
integration of Ca2+-calmodulin signal in intact ventricular myocytes at 
low and high affinity Ca2+-calmodulin targets. J. Biol. Chem. 283, 
31531–31540 (2008). 
78. Bell, J. R., Curl, C. L., Ip, W. T. K. & Delbridge, L. M. D. International 
Journal of Cardiology. International Journal of Cardiology 1–7 (2011). 
doi:10.1016/j.ijcard.2011.02.038 
79. Amici, M. et al. Neuronal calcium sensors and synaptic plasticity. 
Biochem. Soc. Trans 37, 1359 (2009). 
80. Okamoto, K., Bosch, M. & Hayashi, Y. The Roles of CaMKII and F-
Actin in the Structural Plasticity of Dendritic Spines: A Potential 
Molecular Identity of a Synaptic Tag? Physiology 24, 357–366 (2009). 
81. Saucerman, J. J. & Bers, D. M. Journal of Molecular and Cellular 
Cardiology. Journal of Molecular and Cellular Cardiology 1–5 (2011). 
doi:10.1016/j.yjmcc.2011.06.005 
82. VILAPETROFF, M. et al. CaMKII inhibition protects against necrosis 
and apoptosis in irreversible ischemia–reperfusion injury. 
Cardiovascular Research 73, 689–698 (2007). 
83. Passier, R. et al. CaM kinase signaling induces cardiac hypertrophy 
and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105, 
1395–1406 (2000). 
84. Schott, P. et al. Proteome changes in CaMKII. Cardiovascular 
Pathology 19, e241–e250 (2010). 
85. de Tombe, P. P. & Granzier, H. L. The cytoskeleton and the cellular 
transduction of mechanical strain in the heart: a special issue. Pflugers 
Arch - Eur J Physiol 462, 1–2 (2011). 
86. Anh, D. J. et al. Characterization of human coronary sinus valves by 
direct visualization during biventricular pacemaker implantation. 
Pacing Clin Electrophysiol 31, 78–82 (2008). 
87. Eversull, C. S. et al. Direct visualization of cardiac radiofrequency 
ablation lesions. J Cardiovasc Transl Res 2, 198–201 (2009). 
88. Anh, D. J. et al. Early human experience with use of a deflectable 
fiberoptic endocardial visualization catheter to facilitate coronary sinus 
cannulation. HRTHM 3, 875–878 (2006). 
89. Irani, A. R. et al. Visualizing ablation gaps in vitro using a deflectable 
	 98	
fiber optic endocardial visualization catheter. J Interv Card 
Electrophysiol 25, 107–110 (2009). 
90. LaPage, M. J. & Saul, J. P. Update on rhythm mapping and catheter 
navigation. Curr Opin Cardiol 26, 79–85 (2011). 
91. Hameedullah, I. & Chauhan, V. S. Clinical considerations for allied 
professionals: understanding and optimizing three-dimensional 
electroanatomic mapping of complex arrhythmias--part 1. Heart 
Rhythm 6, 1249–1252 (2009). 
92. Metzner, A. et al. One-year clinical outcome after pulmonary vein 
isolation using the novel endoscopic ablation system in patients with 
paroxysmal atrial fibrillation. Heart Rhythm 8, 988–993 (2011). 
93. Gerstenfeld, E. P. & Michele, J. Pulmonary vein isolation using a 
compliant endoscopic laser balloon ablation system in a swine model. 
J Interv Card Electrophysiol 29, 1–9 (2010). 
94. Rohde, G. K., Dawant, B. M. & LIN, S.-F. Correction of motion artifact 
in cardiac optical mapping using image registration. IEEE Trans 
Biomed Eng 52, 338–341 (2005). 
95. KONG, W., WALCOTT, G. P., SMITH, W. M., JOHNSON, P. L. & 
KNISLEY, S. B. Emission Ratiometry for Simultaneous Calcium and 
Action Potential Measurements with Coloaded Dyes in Rabbit Hearts: 
Reduction of Motion and Drift. Journal of Cardiovascular 
Electrophysiology 14, 76–82 (2003). 
96. Phillips, K. P. et al. Anatomic location of pulmonary vein electrical 
disconnection with balloon-based catheter ablation. Journal of 
Cardiovascular Electrophysiology 19, 14–18 (2008). 
97. FRCS-CTh, K. K. D. et al. Adult heart transplantation with distant 
procurement and ex-vivo preservation of donor hearts after circulatory 
death: a case series. Lancet 385, 2585–2591 (2015). 
98. Page, A. A., Messer, S., Tsui, S. S. & Large, S. R. Early Results Using 
Donation After Circulatory Death (DCD) Donor Hearts. Curr Transpl 
Rep 1–8 (2016). doi:10.1007/s40472-016-0106-9 
99. Messer, S. J. et al. Functional assessment and transplantation of the 
donor heart after circulatory death. J Heart Lung Transplant 35, 1443–
1452 (2016). 
 
